

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



PART 04 #16
09/810796

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶:
C12N 5/10, 15/12, 15/63

A1

(11) International Publication Number: WO 99/07832

(43) International Publication Date: 18 February 1999 (18.02.99)

(21) International Application Number: PCT/US98/13276

(22) International Filing Date: 26 June 1998 (26.06.98)

(30) Priority Data: 60/055,599 12 August 1997 (12.08.97) US

(71) Applicant: BRISTOL-MYERS SQUIBB COMPANY
[US/US]; P.O. Box 4000, Princeton, NJ 08543-4000 (US).

(72) Inventors: BLANAR, Michael, A.; 1325 Summerhill Drive, Malvern, PA 19355 (US). DWORETZKY, Steven; 43 High Meadow Lane, Middlefield, CT 06455 (US). YANG, Wen-Pin; 25 Rutgers Lane, Princeton, NJ 08540 (US). LEVESQUE, Paul, C.; 1925 Westover Road, Yardley, PA 19067 (US). GRIBKOFF, Valentin, K.; 142 Williams Road, Wallingford, CT 06492 (US). NEUBAUER, Michael, G.; 7 Cypress Point Court, Skillman, NJ 08558 (US). LITTLE, Wayne, A.; 1206 Chestershire Place, Pottstown, PA 19465 (US).

(74) Agents: KLEIN, Christopher, A. et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: KCNQ POTASSIUM CHANNELS AND METHODS OF MODULATING SAME

(57) Abstract

The present invention relates to KCNQ proteins defining potassium channels. In particular, the invention concerns the human KCNQ2, human KCNQ3, murine KCNQ2, and rat KCNQ2 proteins reported herein. KCNQ2 and KCNQ3 proteins are nervous system-selective and may be involved in neurotransmission and neuroprotection. The KCNQ2 and KCNQ3 of the present invention can be used to assay for modulators of the proteins, which would be useful in treatment of such disorders as ataxia, myokymia, seizures, Alzheimer's disease, Parkinson's disease, age-associated memory loss, learning deficiencies, motor neuron diseases, epilepsy, stroke, and the like.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

KCNQ POTASSIUM CHANNELS AND METHODS OF MODULATING SAME

Field of the Invention

The present invention concerns nucleic acids and proteins for potassium channels, as well as related vectors, host cells, processes for preparation, and methods of use. Included within the present invention are methods of screening for compounds that bind to and/or otherwise modulate the potassium channel proteins disclosed herein. Additionally, the present invention encompasses methods of modulating the potassium channels disclosed herein, for example methods of opening/activating or closing/inactivating said potassium channels.

10

Background of the Invention

Among ion channels, potassium ion (K^+) channels are the most ubiquitous and diverse. They include three major structural classes - channels with six, four, or two transmembrane domains. The six transmembrane domain potassium channels are divided further into different families, such as Shaker-like, eag-like and Slo-like potassium channels. Recent identification of KvLQT1 established a new family of six-transmembrane potassium channels. Barhanin *et al.* (1996) *Nature* 384: 78-80; Sanguinetti *et al.* (1996) *Nature* 384: 80-83; Yang *et al.* (1997) *Proc. Natl. Acad. Sci. USA* 94: 4017-22; Wang *et al.* (1996) *Nature Genetics* 12: 17-23. Search of DNA and protein sequence databanks reveals additional potential members of KvLQT1-related channels in *C. elegans* as well as in the human. Wei *et al.* (1996), *Neuropharmacology* 35: 805-29; ; Yang *et al.* (1997) *Proc. Natl. Acad. Sci. USA* 94: 4017-2.

One or more types of K^+ channels reside on cell membranes where they are remarkably selective for K^+ over other ions. In excitable cells, K^+ channels modulate action potential configuration. Efflux of potassium is the major mechanism for repolarization, maintenance, and hyperpolarization of resting membrane potential. Halliwell (1990) in Potassium channels-structure, classification, function and therapeutic potential (N. S. Cook, ed.); 348-381; Jan, L. Y. and Jan, Y. N. (1992), *Ann. Rev. Physiol.* 54: 537-55; Pongs (1992), *Physiol. Rev.* 72: S69-S88.

In neurons, K⁺ channels regulate neuronal excitability, action potential shape and firing pattern, and neurotransmitter release. These channels can be gated by various stimuli, such as intracellular second messengers, membrane potential, ions, and neurotransmitters. Hille (1992), Ionic channels of excitable membranes; Catterall
5 (1995), Ann. Rev. Biochem. 64: 493-531. Neuronal K⁺ channels are critical to such neuronal functions as neurotransmission and neuroprotection, and they may affect perception, learning, behavior, and the like.

Recently, the nomenclature for KvLQT1 and the KvLQT1-related channels was changed. Biervert *et al.* (1998), Science 279:403-406. KvLQT1 was re-named
10 KCNQ1, and the KvLQT1-related channels (KvLR1 and KvLR2) were re-named as KCNQ2 and KCNQ3, respectively. Therefore, throughout this specification, reference to KCNQ1 is equivalent to KvLQT1; reference to KCNQ2 is equivalent to KvLR1; and reference to KCNQ3 is equivalent to KvLR2.

Benign familial neonatal convulsions ("BFNC"), a class of idiopathic
15 generalized epilepsy, is an autosomal-dominantly inherited disorder of newborns. BFNC has recently been linked to mutations in two putative K⁺ channel genes, KCNQ2 and KCNQ3. Biervert *et al.*, *supra*; Charlier *et al.* (1998), Nature Genetics 18:53-55; Singh *et al.* (1998) Nature Genetics 18:25-29. Preliminary functional characterization of KCNQ2 confirmed that this gene encodes a voltage-activated K⁺
20 channel. Singh *et al.*, *supra*.

Summary of the Invention

The present invention discloses novel nervous system-specific potassium channels referred to herein as KCNQ2 (formerly called KvLR1) and KCNQ3
25 (formerly called KvLR2). Within the present invention are human-KCNQ2 (Figure 2), human KCNQ3 (Figure 23), murine KCNQ2 (Figure 10), and rat KCNQ2 (Figure 16 and Figure 17). The invention encompasses the amino acid sequences of these proteins and the nucleic acid sequences encoding said proteins, as well as variations in the nucleic acid sequences due to degeneracy in the genetic code.

The present invention provides for nucleic acid molecules at least about 70% identical to the consensus sequence of the nucleotide sequences disclosed herein.

Preferably, the present invention provides: (a) a purified and isolated nucleic acid molecule encoding a KCNQ2 and/or KCNQ3 protein of the present invention; (b)

5 nucleic acid sequences complementary to (a); (c) nucleic acid sequences having at least 70% sequence identity, more preferably at least 80%, more preferably at least 90%, more preferably at least 95%, and most preferably at least 98% sequence identity to (a); or (d) a fragment of (a) or (b) which will hybridize to (a) or (b) under stringent conditions, said fragment preferably comprising at least 15 nucleotides.

10 Preferred nucleic acid sequences encoding the KCNQ2 and KCNQ3 proteins of the present invention are found in SEQ ID NO:3, SEQ ID NO:17, SEQ ID NO:7 and SEQ ID NO:5.

Also within the scope of the present invention are amino acid sequences at least about 70% identical to the consensus sequence of the proteins disclosed herein.

15 Preferably, the invention covers: (a) amino acid sequences comprising the KCNQ2 and/or KCNQ3 proteins of the present invention; and (b) amino acid sequences having at least 70% sequence identity, more preferably at least 80%, more preferably at least 90%, more preferably at least 95%, and most preferably at least 98% sequence identity to (a). Preferred amino acid sequences comprising the KCNQ2 and KCNQ3

20 proteins of the present invention are found in SEQ ID NO:4, SEQ ID NO:18, SEQ ID NO:8 and SEQ ID NO:6.

The invention further concerns novel nucleic acids and associated vectors, host cells, and methods of use. Preferably, the nucleic acid molecule is a DNA molecule.

Further preferred are nucleotide sequences encoding the amino acid sequences of SEQ
25 ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, and SEQ ID NO:18 as well as proteins about 70% or more identical to these sequences. Also preferred are nucleotide sequences about 80% or more identical to SEQ ID NO:1; most preferred are SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7 and SEQ ID NO:17.

The invention further concerns nucleic acids obtained by PCR with degenerate
30 oligonucleotide primers. Persons of ordinary skill in the art could devise such primers

based on the consensus sequence described herein. PCR techniques are described in White et al. (1989), Trends Genet. 5: 185-9.

This invention further concerns nucleic acid vectors comprising a nucleic acid sequence coding for a KvLR/KCNQ protein, host cells containing such vectors, and polypeptides comprising the amino acid sequence of a KvLR/KCNQ protein. Preferably, the vector encodes a full-length KvLR/KCNQ protein and the polypeptide is full-length KvLR/KCNQ protein. The inventors prefer frog expression vectors such as pSP64T or derivatives thereof (Melton et al. (1984), Nucl. Acids Res. 12: 7057-70); mammalian cell expression vectors such as pcDNA3 (available from Invitrogen); or bacterial cell expression vectors such as pET-30 (available from Novagen or Promega).

This invention further concerns host cells transformed with the above-described vectors. The inventors prefer Xenopus oocytes, mammalian cells (e.g., HEK293, CHO, L929), and bacterial cells (e.g., E. coli, especially BL21(DE3), available from Novagen). The inventors particularly prefer the cells deposited as ATCC Acc. No. CRL-1573 (American Type Culture Collection, 10801 University Boulevard, Manassas VA 20110-2209).

The invention also concerns methods for detecting nucleic acids coding for KCNQ/KvLR proteins and processes for detecting molecules that bind to and/or otherwise modulate the activity of KCNQ/KvLR proteins. "Modulate" encompasses both channel openers/activators and channel closers/inactivators.

The invention also concerns methods of modulating the KCNQ proteins, specifically methods of opening/activating or closing/inactivating the KCNQ2 and/or KCNQ3 channels. Additionally, the present invention encompasses a method of treating disease by modulating the activity of the KCNQ proteins.

All references cited herein, whether *supra* or *infra*, are hereby incorporated herein in their entirety.

Description of the Drawings

Figure 1 shows isolation of a full-length human KCNQ2/KvLR1 cDNA. A full-length human KCNQ2/KvLR1 cDNA was derived from two overlapping cDNA

clones. "S1" through "S6" signify transmembrane domains 1 through 6; "H5" signifies the pore-forming domain (this domain is also referred to herein as the "P" domain); ORF, the open-reading frame; 3' UTR, the 3' untranslated regions. The locations of various EST clones and probes also are shown. (The figure is not drawn to scale.)

Figures 2A and 2B show the nucleotide and deduced amino acid sequence of human KCNQ2/KvLR1.

Figure 3 shows a sequence comparison of human KCNQ2/KvLR1 and human KCNQ1/KvLQT1. "|" denotes amino acid sequence identity. The C-terminal amino acids of both proteins are not shown.

Figure 4 shows a sequence comparison of human KCNQ3/KvLR2 and human KCNQ1/KvLQT1. "|" denotes amino acid sequence identity. The C-terminal amino acids of both proteins are not shown. The N terminal amino acids of KCNQ3/KvLR2 are not shown.

Figure 5 shows expression of KCNQ2/KvLR1 and KCNQ3/KvLR2 in human tissues and various portions of human brain. Figure 5A shows KCNQ2/KvLR1. Figure 5B shows KCNQ3/KvLR2. Poly(A⁺) mRNA Northern blots were hybridized individually to radiolabeled KCNQ2-specific (Figure 5A) or KCNQ3-specific (Figure 5B) probes. RNA molecular weight markers are indicated on the left.

Figure 6 shows functional characterization of KCNQ2/KvLR1 currents in Xenopus oocytes.

In Figures 6A and 6B, families of currents from water-injected (Figure 6A) and human KCNQ2/KvLR1 cRNA-injected (Figure 6B) oocytes were elicited by 1 second voltage steps, from a holding potential of -80 mV, to test potentials ranging from -100 to +40 mV in 10 mV increments.

Figure 6C shows the peak current-voltage (I-V) relationship for oocytes expressing human KCNQ2/KvLR1. Currents were recorded using the protocol described above for Figures 6A and 6B.

Figure 6D shows dependence of tail current reversal potential (E_{rev}) on the external K⁺ concentration. Tail currents were elicited at potentials of -110 to +10 mV following a 1 second pulse to +20 mV (n = 6 oocytes) while the external K⁺

concentration was varied between 2, 10, 40, and 98 mM. E_{rev} under each condition was determined for each oocyte by measuring the zero intercept from a plot of tail current amplitude versus test potential. The dashed line has a slope of 58 mV and is drawn according to the Nernst equation for a perfectly selective K^+ channel. Data are the mean \pm SEM from six experiments.

Figure 7 shows pharmacologic characterization of KCNQ2/KvLR1 currents in Xenopus oocytes. In particular, this figure shows effects of E-4031, 4-AP, TEA, charybdotoxin and clofilium on human KCNQ2/KvLR1 current. Superimposed currents were recorded during 1 second steps to +30 mV, from -80 mV, during the same experiment. Compounds were applied via bath perfusion in order from top to bottom. The bath was perfused with control solution for 5 minutes, or until effects reversed completely, between compounds. Similar results were obtained in three additional oocytes.

Figure 8 shows co-expression of minK and human KCNQ2/KvLR1 in Xenopus oocytes.

Figure 8A shows the effect of 1 mM TEA on membrane currents recorded from an oocyte injected with human KCNQ2/KvLR1 alone. Superimposed currents were recorded during 1 second voltage steps to +40 mV from a holding potential of -80 mV before and after applying TEA via the bath. TEA reduced human KCNQ2/KvLR1 current by over 80%.

Figure 8B shows the effect of 1 mM TEA on membrane currents recorded from an oocyte injected with minK and human KCNQ2/KvLR1. Currents were elicited using the protocol in Figure 8A. TEA partially inhibited minK + human KCNQ2/KvLR1 currents, however, the amplitude and kinetics of the TEA-insensitive current component were similar to currents observed in oocytes injected with minK alone.

Figure 9 shows murine KCNQ2/KvLR1 expression in the brain of adult mouse. Figure 9A is a dark-field photograph from a coronal section through an adult mouse brain hybridized with a radiolabeled antisense KCNQ2/KvLR1 probe, showing KCNQ2/KvLR1 transcripts in the pyramidal cell layers of the hippocampus. Lower levels of expression were detected in the granular cell layer of the dentate gyrus.

Figure 9B is a dark-field photograph from a similar region as shown in Figure 9A, but hybridized with a sense probe; little KvLR1-specific expression was detected with this probe. Magnification: 125x for both Figure 9A and Figure 9B.

Figure 9C shows partial murine KCNQ2/KvLR1 nucleotide sequence (SEQ ID NO:9) and amino acid sequence (SEQ ID NO:10). This sequence was obtained through PCR amplification of a mouse brain cDNA library using the oligonucleotides MABms 278 (SEQ ID NO:11) and MABms 315 (SEQ ID NO:12) based on the human KCNQ2/KvLR1 sequence. The PCR fragments were isolated, subcloned, and sequenced. A 226 bp fragment as shown above was used in a probe for *in situ* hybridization. The nucleotide sequence is 80% identical to human KCNQ2/KvLR1 (96% identity in amino acid sequence).

MABms 278 (SEQ ID NO:11):

5'-GGCCGAATTCTGTTTCTCAGCAGCTCCAGC-3'

MABms 315 (SEQ ID NO:12):

5'-GCGCGAATTCGAGCAGCACAGGCA(A/G)AA(A/G)CA-3'

Figure 10A through Figure 10D show the DNA and translated amino acid sequence of the mouse brain KCNQ2/KvLR1 gene. Figure 10E shows hydropathy analysis of the mouse brain KCNQ2/KvLR1 gene. The hydropathy plot reveals the pattern typical of voltage-sensitive K⁺ channels with 6 putative membrane spanning domains (S1-S6) and a pore region (P).

Figure 11 shows sequence alignment of the mouse heart KCNQ1/KvLQT1 and mouse brain KCNQ2/KvLR1 potassium channels. The alignment of these two genes shows a 40% overall amino acid identity (indicated by the shaded areas) and 62.5% identity within the spanning and pore domains. Putative membrane spanning and pore domains are indicated by the boxes. The signature sequence for a potassium channel, GYG, is observed within the pore region and the voltage sensor, RXXQXXRXXR, is within the S4 domain.

Figure 12 shows alternative splice exons in the 3' end of murine KCNQ2/KvLR1. At least two splice exons, that when translated give the amino acid sequences shown in A and B (SEQ. ID. NOS.: 13 and 14), have been identified in the murine KCNQ2/KvLR1 gene at amino acid positions 372 and 406, respectively.

Figure 13 shows a mouse multiple tissue northern blot. A northern blot was probed with a fragment of the mouse KCNQ2/KvLR1 gene (nucleotides 1140-2306). A single transcript of 8.2 kb is observed in brain, but not is seen in other tissues.

Figure 14 shows in situ hybridization of rat brain. The composite shows three regions where the rat KCNQ2/KvLR1 message is strongly expressed. The antisense probes show strong signal in the hippocampus, dentate gyrus, cortex, and motor nucleus of the trigeminal nerve. Sense probe controls show little background.

Figure 15 shows electrophysiology characterization of mouse KCNQ2/KvLR1-mediated whole-cell currents expressed in Xenopus oocytes. In Figure 15A, 10 mV step depolarizations from a -80 to +40 produced a family of outward currents that were significantly different than control cells. Addition of 1 mM TEA blocked the KvLR1-mediated currents and background chloride currents were not affected by TEA. Clofilium, a blocker of heart I_{Ks} and I_{Kr} currents, was shown to partially block the KCNQ2/KvLR1-mediated currents when depolarized to from -80 to +40 μ V. Figure 15B shows uninjected controls.

Figure 16 shows an alignment of the consensus nucleotide sequence (SEQ ID NO:1) and the nucleotide sequences of the human KCNQ3/KvLR2 (SEQ ID NO:17), human KCNQ2/KvLR1 (SEQ ID NO:3), mouse KCNQ2/KvLR1 (SEQ ID NO:5), and rat KCNQ2/KvLR1 (SEQ ID NO:7). “[” denotes sequence identity; “-” represents non-consensus sequence; and “*” denotes a space introduced to optimize sequence identity.

Figure 17 shows an alignment of the consensus amino acid sequence (SEQ ID NO:2) and the amino acid sequences of the human KCNQ3/KvLR2 (SEQ ID NO:18), human KCNQ2/KvLR1 (SEQ ID NO:4), mouse KCNQ2/KvLR1 (SEQ ID NO:6), and rat KCNQ2/KvLR1 (SEQ ID NO:8) proteins. As in Figure 16, “[” denotes sequence identity; “-” represents non-consensus sequence; and “*” denotes a space introduced to optimize sequence identity.

Figure 18 shows the functional characterization of KCNQ3 currents. Figure 18A shows families of currents from KCNQ3 cRNA-injected oocytes elicited by 1 sec voltage steps, from a holding potential of -80 mV, to test potentials ranging from -70 to +50 mV in 10 mV increments. Figure 18B shows I-V relationship for oocytes

expressing KCNQ3 (n=6). Currents were recorded using the protocol in Figure 18A.

Figure 18C shows dependence of tail current E_{rev} on the external K^+ concentration.

The line has a slope predicted by the Nernst equation for a perfectly selective K^+ channel. Each value is the mean \pm SEM from 6 oocytes. Figure 18D shows effects of

5 E-4031, 4-AP, TEA and clofilium on KCNQ3 current. Superimposed currents were recorded during 1 sec steps to +20 mV, from -80 mV, during the same experiment. Compounds were applied via bath perfusion in order from top to bottom. The bath was perfused with control solution for 5 min, or until effects reversed completely, between compounds. Similar results were obtained in three additional oocytes.

10 Figure 19 shows co-expression of KCNQ2 and KCNQ3. Figure 19A shows families of currents from KCNQ2, Figure 19B from KCNQ3, and Figure 19C from KCNQ2+KCNQ3 cRNA-injected oocytes elicited by 1 sec voltage steps, from a holding potential of -80 mV, to test potentials ranging from -70 to +50 mV (10 mV increments). Figure 19D shows current-voltage (I-V) relationship for oocytes
15 expressing KCNQ2+KCNQ3 (n=6). Currents were recorded using the protocol in Figures 19A-19C. Figure 19E shows dependence of tail current reversal potential (E_{rev}) on the external K^+ concentration. The dashed line has a slope predicted by the Nernst equation for a perfectly selective K^+ channel. Each value is the mean \pm SEM from 6 oocytes. Figure 19F shows the effects of 4-AP, TEA, charybdotoxin and
20 clofilium on KCNQ2+KCNQ3 current. Superimposed currents were recorded during 1 sec steps to +20 mV, from -80 mV, during the same experiment. Compounds were applied via bath perfusion in order from top to bottom. Similar results were obtained in 4 additional oocytes.

Figure 20 shows the interaction of KCNE1 (minK) with KCNQ2+KCNQ3
25 currents. Families of currents from KCNE1 (Figure 20A), KCNQ2+KCNQ3 (Figure 20B) and KCNQ2+KCNQ3+KCNE1 (Figure 20C) cRNA-injected oocytes elicited by 1 sec voltage steps, from a holding potential of -80 mV, to test potentials ranging from -70 to +50 mV (10 mV increments). Inset of Figure 20A shows KCNE1 currents elicited by 5 sec voltage steps from -80 mV to potentials ranging from -30 to +50 mV
30 (20 mV increments) in the same oocyte.

Figure 21 is a photograph of in situ hybridization with rat KCNQ2 showing a cross section of the rat spinal cord. Figure 21(A) is under low magnification (55x); several areas can be visualized with a relatively high signal. Figure 21(B) is under higher magnification (322x); each high signal area is one cell and they appear by their size to be motoneurons.

Figure 22A shows macroscopic murine KCNQ2 current recorded from inside-out membrane patch excised from a CHO cell stably expressing murine KCNQ2. The current displays slow activation and outward rectification. Figure 22B shows patch clamp recording of single channel currents in an excised inside-out patch from a CHO/murine KCNQ2 cell. There are at least 2 channels in the patch; single channel conductance of KCNQ2 was estimated to be between 24 and 30 pS. All recordings were made in symmetrical 140 mM K⁺ using standard techniques.

Figure 23 shows the nucleotide and deduced amino acid sequence of human KCNQ3 (also referred to herein as KvLR2).

Detailed Description of the Invention

The following definitions apply to the terms used throughout this specification, unless otherwise defined in specific instances:

"cloning" - isolation of a particular gene from genetic material, for example a genome, genomic library, or cDNA library into a plasmid or other vector;

"KvLR protein" - a protein having at least about 70% identity with the consensus sequence (SEQ. ID. NO.: 2). It may also be referred to as a "KCNQ protein", "KvLR/KCNQ protein" or "KCNQ/KvLR protein".

"KCNQ1" - the protein formerly known as KvLQT1.

"KCNQ2" - the protein formerly known as KvLR1.

"KCNQ3" - the protein formerly known as KvLR2.

"stringent conditions" (as used concerning nucleic acid hybridization)—For example, Southern blotting washed in 1 X SSC and 0.1% SDS at a temperature of at least about 42 °C. For additional stringent conditions, see Maniatis *et al.*, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1982).

"multi-copy plasmid"—a plasmid having greater than one copy present in a cell
(typically 10 to 30 copies);

"Northern blotting"—a method of identifying particular RNA fragments by
hybridization with a complementary nucleic acid, typically a cDNA or an
oligonucleotide;

"open reading frame" or "ORF"—a DNA sequence containing a series of nucleotide
triplets coding for amino acids and lacking any termination codes;

"plasmid"—cytoplasmic, autonomously replicating DNA elements found in
microorganisms;

"promoter"—a region on DNA at which RNA polymerase binds and initiates
transcription; and

"Southern blotting"—a method of identifying particular DNA fragments by
hybridization with a complementary nucleic acid, typically a cDNA or an
oligonucleotide.

For definitions of other terms in this specification, see F. Sherman *et al.*,
Laboratory Course Manual for Methods in Yeast Genetics, Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY (1987) and Lewin, B., Genes IV, Oxford
University Press, Oxford (1990).

The following definitions apply to abbreviations in this specification, unless
otherwise defined in specific instances:

BFNC	benign familial neonatal convulsions
BLAST	basic local alignment search tool
CHO	Chinese hamster ovary cells
DTT	dithiothreitol
DRG	dorsal root ganglion
EDTA	ethylene diamino tetraacetic acid
EST	expressed sequence tags
GPCR	G-protein-coupled receptor
ORF	open reading frame
PAGE	polyacrylamide gel electrophoresis
PBS	phosphate buffered saline

PCR	polymerase chain reaction
SDS	sodium dodecyl sulfate
SSC	buffer containing 150 mM NaCl, 15 mM Na ₃ citrate • 2 H ₂ O, pH 7.0.
5 TEA	tetraethylammonium

For additional abbreviations, see Aldrichimica Acta, Vol. 17, No. 1 (1984).

Use and utility

It is believed by those skilled in the art that KCNQ proteins may be involved in neurotransmission. Persons of ordinary skill in the art can use KCNQ/KvLR
10 proteins of the present invention to assay for modulators of KCNQs/KvLRs. KCNQ modulators would be useful in treatment of such disorders as ataxia, myokymia, seizures (e.g., epileptic seizures), Alzheimer's disease, Parkinson's disease, age-associated memory loss, learning deficiencies, motor neuron diseases, stroke, and the like.

15 Because KCNQ2 and KCNQ3 are nervous system-selective potassium channels, drug specificity is built into any KCNQ2/KCNQ3-specific modulator. A drug specific for KCNQ2 and/or KCNQ3 protein would thus avoid side-effects on peripheral tissues that contain potassium channels. Significantly, KCNQ2/KCNQ3-specific modulators would avoid side-effects on the heart, which contains numerous
20 types of potassium channels.

The KCNQ nucleic acids of the present invention, or antisense nucleic acids, may be useful therapeutic or diagnostic agents. For such gene therapy, the nucleic acids may be incorporated into vectors and/or formulated as described below and in further detail in the art.

25 Persons skilled in the art can use the polypeptides and nucleic acids of this invention to prepare vectors, cells or cell lines, and antibodies. All of these are useful in assays for identification of KCNQ2/KCNQ3 protein modulators.

One can administer KCNQ2 and/or KCNQ3 protein modulators to various mammalian species, such as monkeys, dogs, cats, mice, rats, humans, etc. By known
30 methods, persons skilled in the pharmaceutical art can incorporate KCNQ2/KCNQ3 protein modulators in a conventional systemic dosage form, such as a tablet, capsule,

elixir or injectable formulation. The above dosage forms will also include any necessary physiologically acceptable carrier material, excipient, lubricant, buffer, antibacterial, bulking agent (such as mannitol), anti-oxidants (ascorbic acid or sodium bisulfite) or the like.

5 **Process of preparation**

In general

This specification describes the cloning and functional expression of full-length human cDNA clones of KCNQ2 (KvLR1) and KCNQ3 (KvLR2), preferably the human KCNQ2 nucleic acid sequence (Figure 2) as shown in SEQ ID NO:3, the
10 human KCNQ2 amino acid sequence (Figure 2) as shown in SEQ ID NO:4, the human KCNQ3 nucleic acid sequence (Figure 23) as shown in SEQ ID NO:17, and the human KCNQ3 amino acid sequence (Figure 23) as shown in SEQ ID NO:18. Also disclosed is a full-length murine cDNA clone of KCNQ2 (murine KvLR1; Figure 10), preferably the murine KCNQ2 nucleic acid sequence as shown in SEQ ID
15 NO:5, and the murine KCNQ2 amino acid sequence as shown in SEQ ID NO:6. Additionally, the present invention covers a rat KCNQ2 sequence (Figure 16 and Figure 17), preferably the rat KCNQ2 nucleic acid sequence as shown in SEQ ID NO:7, and the rat KCNQ2 amino acid sequence as shown in SEQ ID NO:8. The gating kinetics and macroscopic current properties of human, murine and rat KCNQ2
20 and KCNQ3 currents are similar to those of KCNQ1. However, KCNQ2 and KCNQ3 are specifically localized within the nervous system and have different pharmacological properties.

DNA clones comprising nucleotide sequences encoding the following KCNQ2 and KCNQ3 proteins of the present invention were deposited with the
25 American Type Culture Collection ("ATCC") (10801 University Blvd., Manassas, VA 20110-2209) on _____, 1998: human KCNQ2, ATCC Accession Number _____; human KCNQ3, ATCC Accession Number _____; and murine KCNQ2, ATCC Accession Number _____. The deposit(s) referred to herein will be maintained under the terms of the Budapest Treaty on the International
30 Recognition of the Deposit of Micro-organisms for purposes of Patent Procedure. These deposits are provided merely as convenience to those of skill in the art and are

not an admission that a deposit is required under 35 U.S.C. 112. The sequence of the polynucleotides contained in the deposited materials, as well as the amino acid sequence of the of the polypeptides encoded thereby, are incorporated herein by reference and are controlling in the event of any conflict with any description of sequences herein. A license may be required to make, use or sell the deposited materials, and no such license is hereby granted.

Nucleic acids

With the human KCNQ2, human KCNQ3, murine KCNQ2, and rat KCNQ2 gene sequences in hand, one skilled in the art can obtain KCNQ nucleic acids of this invention by known methods. Such methods include: (1) Southern and Northern blotting; (2) Western immunoblotting; (3) chemical synthesis; (4) synthesis by polymerase chain reaction (PCR) from primers; (5) expression cloning; and (6) subtractive cDNA cloning.

Persons skilled in the art can also modify the nucleic acids coding for the KCNQ proteins of the present invention to prepare useful mutations. For example, one may modify the sequence to provide additional restriction endonuclease recognition sites in the nucleic acid. Such mutations may be silent or may change the amino acid encoded by the mutated codon. One can prepare these modified nucleic acids, for example, by mutating the nucleic acid coding for KCNQ2 to result in deletion, substitution, insertion, inversion or addition of one or more amino acids in the encoded polypeptide. For methods of site-directed mutagenesis, see Taylor, J. W. *et al.* (1985), Nucl. Acids Res. 13, 8749-64 and Kunkel, J. A. (1985), Proc. Natl. Acad. Sci. USA 82: 482-92. In addition, kits for site-directed mutagenesis are available from commercial vendors (e.g., BioRad Laboratories, Richmond, CA; Amersham Corp., Arlington Heights, IL). For disruption, deletion and truncation methods, see Sayers, J. R. *et al.* (1988), Nucl. Acids Res. 16: 791-800.

This invention also comprises modified nucleic acids, including (1) alternative splice exon variants; (2) allelic variants; and (3) chimeric channels in which the fusion construct comprises a KCNQ modulatory site. Such modified nucleic acids can be obtained by persons of ordinary skill in the art when armed with the present disclosure.

Expression vectors

This invention further concerns expression vectors comprising a nucleotide sequence encoding a KCNQ protein of the present invention. Preferably, the expression vectors comprise all or a portion of the nucleic acid sequence as shown in
5 SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, or SEQ ID NO:17.

Expression vectors are usually plasmids, but the invention includes other vector forms that serve equivalent functions and become known in the art subsequently hereto. A person skilled in the art might also stably integrate a sequence encoding a KCNQ protein into the chromosome of an appropriate host cell.

10 Expression vectors typically contain regulatory elements capable of affecting expression of a KCNQ protein. These regulatory elements can be heterologous or native KCNQ elements. Typically, a vector contains an origin of replication, a promoter, and a transcription termination sequence. The vector may also include other regulatory sequences, including mRNA stability sequences, which
15 provide for stability of the expression product; secretory leader sequences, which provide for secretion of the expression product; environmental feedback sequences, which allow expression of the structural gene to be modulated (e.g., by the presence or absence of nutrients or other inducers in the growth medium); marking sequences, which are capable of providing phenotypic selection in transformed host cells;
20 restriction sites, which provide sites for cleavage by restriction endonucleases; and sequences which allow expression in various types of hosts, including prokaryotes, yeasts, fungi, plants and higher eukaryotes.

An expression vector of this invention is at least capable of directing the replication, and preferably the expression, of the nucleic acids and protein of this
25 invention. Suitable origins of replication include, for example, the Col E1, the SV40 viral and the M13 origins of replication. Suitable promoters include, for example, the cytomegalovirus promoter, the lacZ promoter, the gal10 promoter and the Autographa californica multiple nuclear polyhedrosis virus (AcMNPV) polyhedral promoter. Suitable termination sequences include, for example, the bovine growth hormone,
30 SV40, lacZ and AcMNPV polyhedral polyadenylation signals. Examples of

selectable markers include neomycin, ampicillin, and hygromycin resistance and the like.

Persons skilled in the art may insert DNA encoding a KCNQ protein of the present invention into several commercially available vectors. Examples include
5 vectors compatible with mammalian cells, such as pcDNA3 or pCEP4; baculovirus vectors such as pBlueBac; prokaryotic vectors such as pcDNA2; and yeast vectors such as pYes2. For vector modification techniques, see Sambrook *et al.* (1989), Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

10 Host cells

This invention additionally concerns host cells containing an expression vector that comprises a sequence encoding a KCNQ protein, preferably the KCNQ2 and/or KCNQ3 proteins of the present invention. The host cells preferably contain an expression vector which comprises all or part of the DNA sequence having the
15 nucleotide sequence substantially as shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, or SEQ ID NO:17, particularly the coding regions thereof. Suitable host cells include both prokaryotic cells (e.g., *E. coli* strains HB101, DH5a, XL1 Blue, Y1090 and JM101) and eukaryotic cells (e.g., *Spodoptera frugiperda* insect cells, CHO cells, COS-7 cells, HEK 293 cells, human skin fibroblasts, and *S.*
20 *cerevisiae* cells).

Persons skilled in the art may introduce expression vectors into host cells by various methods known in the art. Exemplary methods are transfection by calcium phosphate precipitation, electroporation, liposomal fusion, nuclear injection, and viral or phage infection. One may then culture the host cell under conditions permitting
25 expression of large amounts of KCNQ protein.

One may identify such modified host cells by any of six general approaches:

(a) DNA-DNA hybridization with probes complementary to the sequence encoding KCNQ protein (Southern blotting).

30 (b) detection of marker gene functions, such as thymidine kinase activity, resistance to antibiotics, and the like. A marker gene can be placed in the same

plasmid as the KCNQ sequence under the regulation of the same or a different promoter.

(c) detection of mRNA transcripts by hybridization assays (e.g., Northern blotting or a nuclease protection assay using a probe complementary to the RNA sequence).

(d) immunodetection of gene expression (e.g., by Western blotting with antibody to KCNQ protein).

(e) detection of potassium channel activity, such as by patch-clamp analysis, radioisotope (e.g., ^{86}Rb) efflux, or membrane potential-sensitive reagents (e.g., Dibac from Molecular Probes International).

(f) PCR with primers homologous to expression vector sequences or sequences encoding KCNQ protein. The PCR produces a DNA fragment of predicted length, indicating incorporation of the expression system in the host cell.

Persons skilled in the art may determine DNA sequences by various known methods. See, for example, the dideoxy chain termination method in Sanger *et al.* (1977), *Proc. Natl. Acad. Sci. USA* 74: 5463-7 and the Maxam-Gilbert method in Maxam-Gilbert (1977), *Proc. Natl. Acad. Sci. USA* 74: 560-4.

One may use the host cells of this invention in a variety of ways that are now apparent. One may use the cells to screen for compounds that bind to or otherwise modulate or regulate the function of KCNQ protein, which would be useful for modulation, for example activation, of KCNQ2 and/or KCNQ3 protein activity; to study signal transduction mechanisms and protein-protein interactions; and to prepare KCNQ protein for the uses described below.

Not all expression vectors and DNA regulatory sequences will function equally well to express the DNA sequences of this invention. Neither will all host cells function equally well with the same expression system. However, one of ordinary skill in the art may make a selection among expression vectors, DNA regulatory sequences, and host cells using the guidance provided herein without undue experimentation and without departing from the scope of the invention.

Polypeptides

This invention further concerns polypeptides comprising all or a portion of the amino acid sequences of a KCNQ2 and/or KCNQ3 protein. The inventors prefer polypeptides comprising all or a portion of the amino acid sequences shown as in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, or SEQ ID NO:18.

5 Where a portion of the KCNQ2 and/or KCNQ3 protein is used, preferably the portion exhibits K⁺ channel activity or can be modulated to exhibit K⁺ channel activity. For example, and within the scope of the invention, are polypeptides that comprise all or a portion of KCNQ2 and/or KCNQ3 that may contain one or more mutations so that the protein(s) fails to exhibit K⁺ channel activity, but that can be used to screen for
10 compounds that will activate the protein or portion thereof.

Persons having ordinary skill in the art may prepare these polypeptides by methods known in the art. For example, one may use chemical synthesis, such as the solid phase procedure described by Houghton *et al.* (1985), *Proc. Natl. Acad. Sci.* 82: 5131-5. Another method is *in vitro* translation of mRNA. One may also produce the
15 polypeptides in the above-described host cells, which is the preferred method. For example, one may synthesize DNA comprising all or a portion of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:17 by PCR as described above, insert the synthesized DNA into an expression vector, transform a host cell with the expression vector, and culture the host cell to produce the desired polypeptides.

20 Persons skilled in the art can isolate and purify such polypeptides by any one of several known techniques; for example, ion exchange chromatography, gel filtration chromatography and affinity chromatography. Such techniques may require modification of the protein. For example, one may add a histidine tag to the protein to enable purification on a nickel column.

25 Persons skilled in the art can use the polypeptides of the invention in a wide variety of ways. For example, one may use them to generate polyclonal or monoclonal antibodies. One may then use such antibodies for immunodetection (e.g., radioimmunoassay, enzyme immunoassay, or immunocytochemistry), immunopurification (e.g., affinity chromatography) of polypeptides from various
30 sources, or immunotherapy (i.e., for potassium channel inhibition or activation).

Persons skilled in the art may make modified KCNQ polypeptides by known techniques. Such modifications may cause higher or lower activity, permit higher levels of protein production, or simplify purification of the protein. Such modifications may help identify specific KCNQ2 and/or KCNQ3 amino acids involved in binding, which in turn may help rational drug design of KCNQ2/KCNQ3 modulators. One can make amino acid substitutions based on similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues involved. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; amino acids with uncharged polar head groups or nonpolar head groups having similar hydrophilicity values include the following: leucine, isoleucine, valine, glycine, alanine; asparagine, glutamine; serine, threonine; phenylalanine, tyrosine. All such modified polypeptides are included within the scope of the invention.

The inventors contemplate a number of other variations of the above-described polypeptides. Such variations include salts and esters of the polypeptides, as well as precursors of the aforementioned polypeptides (e.g., having N-terminal substituents such as methionine, N-formylmethionine and leader sequences). The invention includes all such variations.

Method for detecting nucleic acids

The present invention further concerns a method for detecting nucleic acids encoding KCNQ protein. In this method, a person of ordinary skill in the art (a) contacts nucleic acids of unknown sequence with a nucleic acid having a sequence complementary to a known coding sequence (e.g., a sequence of at least about 10 nucleotides from, e.g., SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, or SEQ ID NO:17, particularly the coding regions thereof), wherein the latter nucleic acid has a detectable marker; and (b) determines the presence of marker bound to any of the nucleic acids of unknown sequence. The presence of bound marker indicates the presence of the desired nucleic acids. One can apply this method to detect KCNQ nucleic acids from other tissues (which may have different regulatory elements) and nucleic acids from other species (e.g., monkey).

Persons of ordinary skill in the art generally know how to obtain nucleic acids to be analyzed in this method. For genomic DNA, one can rapidly freeze tissue, crush the tissue into readily digestible pieces, and incubate the crushed tissue in proteinase K and SDS to degrade most cellular proteins. One can then deproteinize
5 the genomic DNA by successive phenol/chloroform/isoamyl alcohol extractions, recover DNA by ethanol precipitation, dry it and resuspend it in buffer. For RNA, one can lyse cultured cells in 4M guanidinium solution, draw the lysate through a 20-gauge needle, pellet the RNA through a cesium chloride step gradient, and remove the supernatant. The pellet should contain purified RNA.

10 The detectable marker may be a radioactive ion linked to one of the nucleotides of the complementary nucleic acid. Common radioactive labels are ^{32}P and ^{35}S , although one may also use other labels such as biotin. Persons skilled in the art are aware of various methods to attach the labels to the complementary nucleic acid (e.g., the random primer method for attachment of ^{32}P or ^{35}S).

15 Persons of ordinary skill in the art generally know how to carry out such a method of detecting nucleic acids. For example, one may perform a Southern or northern blot using a radiolabeled KCNQ complementary oligonucleotide probe. One can then detect hybridization by autoradiography. Depending on the marker, one may also use other detection methods (e.g., spectrophotometry).

20 Methods for detecting KCNQ2/KCNQ3 protein modulators

This invention further concerns methods for detecting modulators of the KCNQ2 and/or KCNQ3 proteins of the present invention. A screen for KCNQ protein modulators entails detecting binding of molecules (e.g., polypeptides, natural products, synthetic compounds) in cells expressing KCNQ protein.

25 Cloning and sequencing of KCNQ protein enables construction of cells useful in screening for natural products and synthetic compounds that bind to and/or modulate KCNQ protein activity. A process for detecting KCNQ protein modulators requires transforming a suitable vector into compatible host cells as described previously herein. One treats such transformed cells with test substances (e.g.,

synthetic compounds or natural products), and then measures activity in the presence and absence of the test substance.

Gene Therapy

Persons skilled in the art can also use sense and antisense nucleic acid molecules as therapeutic agents for KCNQ-related indications. One may construct
5 vectors that direct the synthesis of the desired DNA or RNA or formulate the nucleic acid as described in the art.

Several references describe the usefulness of antisense molecule. See Toulme and Helene (1988), Gene 72: 51-8; Inouye (1988), Gene, 72: 25-34; Uhlmann
10 and Peyman (1990), Chemical Reviews 90: 543-584; Biotechnology Newswatch (January 15, 1996), p. 4; Robertson, Nature Biotechnology 15: 209 (1997); Gibbons and Dzau (1996), Science 272: 689-93. One can design them based on genomic DNA and/or cDNA, 5' and 3' flanking control regions, other flanking sequences, intron
15 sequences, and nonclassic Watson and Crick base pairing sequences used in formation of triplex DNA. Such antisense molecules include antisense oligodeoxyribonucleotides, oligoribonucleotides, oligonucleotide analogues, and the like, and may comprise at least about 15 to 25 bases.

Antisense molecules may bind noncovalently or covalently to the KCNQ DNA or RNA. Such binding could, for example, cleave or facilitate cleavage of
20 KCNQ DNA or RNA, increase degradation of nuclear or cytoplasmic mRNA, or inhibit transcription, translation, binding of transactivating factors, or pre-mRNA splicing or processing. Antisense molecules may also contain additional functionalities that increase stability, transport into and out of cells, binding affinity, cleavage of the target molecule, and the like. All of these effects would decrease
25 expression of KCNQ protein and thus make the antisense molecules useful as KCNQ protein modulators.

Detailed Description of Preferred Embodiments

Human KCNQ2 and KCNQ3

Genetic properties

KCNQ1-Related (KCNQ2/KCNQ3) expressed sequence tags (ESTs) were
5 discovered by a GCG BLAST search of the GenBank database with KCNQ1
sequence. Primers, derived from the consensus sequences of EST clones, were used to
amplify human brain-derived cDNA and 877 bp and 325 bp fragments were isolated
for KCNQ2 and KCNQ3, respectively. (Figure 1, probe I). To obtain full-length
cDNA sequences of both genes, we employed 5'RACE PCR, screening of cDNA
10 libraries, and Gene Trapper techniques. The composite full-length cDNAs of KCNQ2
(SEQ ID NO:3) and KCNQ3 (SEQ ID NO:17) contain an open reading frame (ORF)
encoding an 871 (SEQ ID NO:4) and 854 (SEQ ID NO:18) amino acid polypeptide,
respectively (Figure 2 and Figure 23). DNA sequence analysis and conceptual
translation of both cDNAs reveals that they encode proteins with the structural
15 features of a voltage-gated potassium channel and are most closely related to KCNQ1.
Sanguinetti *et al.* (1996), *Nature* 384: 80-83; Yang *et al.* (1997), *Proc. Natl. Acad. Sci.*
USA 94:4017-2. KCNQ2 exhibits a high degree of sequence similarity with KCNQ3
($\approx 70\%$), indicating that they belong to the same subfamily. Both proteins have a
longer C-terminal domain (~ 200 amino acids) than KCNQ1. The initiation codon for
20 KCNQ2 is flanked by a consensus ribosome binding site (i.e., Kozak) ACCATGG
(Figure 2).

At the amino acid level, sequence analysis reveals that KCNQ2/KvLR1
contains the GYG (i.e., Gly-Tyr-Gly) potassium channel pore "signature sequence"
and, therefore, is likely to encode a potassium-selective channel. A comparison of
25 KCNQ2 and KCNQ1 (KvLQT1) reveals that the amino acid sequence identity is
approximately 60% in the transmembrane and pore regions (Figure 3). KCNQ3
exhibits about the same degree of identity (about 56%) with KCNQ1 as KCNQ2 in
the transmembrane and pore regions (Figure 4). The identity in the amino-terminal
and carboxy-terminal domain is much less compared to the central conserved regions
30 (Figure 3). Such findings suggest that KCNQ2/KvLR1 and KCNQ3/KvLR2 are
additional members of the KCNQ1/KvLQT1 family of ion channels.

KCNQ2- and KCNQ3-specific transcripts are detectable only in human brain (Figure 5). This expression pattern is distinct from KCNQ1/KvLQT1, which is expressed strongly in human heart and pancreas as revealed by Northern blot analysis. Sanguinetti *et al.* (1996) *Nature* 384: 80-83; Yang *et al.* (1997), *Proc. Natl. Acad. Sci. USA* 94:4017-2. Expression of human KCNQ2/KvLR1 is high in the hippocampus, caudate nucleus, and amygdala; moderate in the thalamus; and weak in the subthalamic nucleus, substantia nigra and corpus callosum (Figure 5). A separate Northern blot demonstrates that expression of human KCNQ2/KvLR1 is high in the cerebral cortex; is moderate in the putamen, temporal lobe, frontal lobe, occipital pole and cerebellum; and is low in the medulla and spinal cord (Figure 5). KCNQ3 exhibits a nearly identical expression pattern in the brain (Figure 5). In order to characterize further the cell types that express KCNQ2/KvLR1, a murine-specific KCNQ2/KvLR1 cDNA fragment was isolated and used as an *in situ* hybridization probe. The result (Figure 9) shows that KCNQ2/KvLR1 is expressed in the mouse hippocampus and dentate gyrus, areas that are important in learning and memory.

Electrophysiological properties

The full-length human KCNQ2 and KCNQ3 cDNAs were subcloned into a *Xenopus* expression vector and cRNA was generated by *in vitro* transcription. The properties of the channels encoded by human KCNQ2 and KCNQ3 were investigated by expressing the transcribed cRNA in *Xenopus* oocytes. Figure 6 compares currents recorded from oocytes that were injected 5 days earlier with either water (Figure 6A) or 14 ng of human KCNQ2/KvLR1 cRNA (Figure 6B). Oocytes injected with human KCNQ2/KvLR1 cRNA exhibited outward currents that activated at potentials positive to -60 mV and had a maximal amplitude of 1 μ A at +40 mV. Similar currents were never observed in water-injected control oocytes and small leak or endogenous currents recorded in control oocytes never exceeded 0.15 mA at +40 mV. The human KCNQ2/KvLR1 currents exhibited a rapidly activating delayed rectifier current phenotype very similar to hKCNQ1/KvLQT1 current. Barhanin *et al.* (1996) *Nature* 384: 78-80; Sanguinetti *et al.* (1996), *Nature* 384: 80-83; ; Yang *et al.* (1997) *Proc. Natl. Acad. Sci. USA* 94:4017-2. KCNQ2/KvLR1 current rectified weakly at positive voltages.

Although the macroscopic KCNQ2/KvLR1 and KCNQ1/KvLQT1 currents are similar, KCNQ2/KvLR1 tail currents lack the "hook" observed with KCNQ1/KvLQT1 tail current. Figure 6C shows the peak current-voltage (IV) relationship for oocytes expressing KCNQ2/KvLR1 ($n = 12$). The K^+ selectivity of the expressed current was examined by investigation of tail current reversal potentials in bath solutions containing 2, 10, 40 and 98 mM K^+ . Reversal potentials closely followed the Nernst potential for K^+ revealing a K^+ -selective channel ($n = 6$; Figure 6D). The reversal potential for KCNQ2/KvLR1 current shifted by 52 mV per 10-fold change in external K^+ . The dashed line has a slope predicted from the Nernst equation for a perfectly selective K^+ channel.

A family of currents elicited by depolarizing voltage steps in an oocyte injected with KCNQ3 cRNA are shown in Figure 18A. The currents activate at potentials positive to -70 mV and rectify inwardly at potentials greater than 0 mV, as is obvious from the IV relationship (Figure 18B). The KCNQ3 reversal potential shifted 49 mV per 10-fold change in external K^+ (Figure 18C). Thus, although still predominantly selective for K^+ , KCNQ3 is slightly less K^+ -selective than KCNQ2.

Co-expression of KCNE1 (KCNE1 is also known as "minK" or "Isk") with KCNQ1/KvLQT1 dramatically alters the amplitude and gating kinetics of KCNQ1/KvLQT1 current. Barhanin *et al.* (1996) *Nature* 384: 78-80; Sanguinetti *et al.* (1996), *Nature* 384: 80-83; ; Yang *et al.* (1997) *Proc. Natl. Acad. Sci. USA* 94:4017-2. MinK is a polypeptide thought to encode or regulate a K^+ channel. Folander *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 87: 2975-2979; Varnum *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90: 11528-11532; Ben-Efraim *et al.* (1996) *J. Biol. Chem.* 271: 8768-8771. These studies suggest that minK and KCNQ1/KvLQT1 co-assemble to form the K^+ channel underlying the slow delayed rectifier current in heart. A similar association between minK and KCNQ2/KvLR1 was tested. Coexpression of KCNE1 with KCNQ2/KvLR1 had little effect on the KCNQ2/KvLR1 current in oocytes, and separate currents carried by KCNQ1/KvLQT1 and KCNQ2/KvLR1 channels could be delineated in oocytes co-injected with minK and KCNQ2/KvLR1 using selective inhibitors for each of the channels. Thus, KCNQ2/KvLR1 interacts

differently with KCNE1 than does KCNQ1/KvLQT1. Different KCNQ members may functionally interact with proteins structurally similar to KCNE1.

Pharmacological properties

Inhibitors of various potassium channels present in brain and other tissues were used to investigate the pharmacology of KCNQ2/KvLR1. The effects of 0.2 mM of 4-aminopyridine (4-AP), 10 μ M E-4031, 10 μ M clofilium, 0.1 mM of charybdotoxin, and 1 mM tetraethylammonium (TEA) on KCNQ2/KvLR1 currents recorded from a single oocyte are shown in Figure 7. Each of these compounds was also tested alone in individual oocytes and the effects of each agent were no different.

Charybdotoxin is a scorpion venom protein that inhibits a variety of Ca^{2+} -activated and voltage-dependent K^{+} channels. Miller *et al.* (1985), *Nature* 313: 316-8; Sugg *et al.* (1990), *J. Biol. Chem.* 265: 18745-8. Charybdotoxin did not inhibit the KCNQ2/KvLR1 current at the concentration tested. This toxin also had no effect on KCNQ1/KvLQT1.

E-4031 (10 mM) is a selective inhibitor of I_{Kr} . Sanguinetti *et al.* (1990) *J. Gen. Physiol.* 96: 195-215). 4-AP (0.2 mM) is an inhibitor of Shaker-type K^{+} channels. Deal *et al.* (1996) *Physiol. Rev.* 76: 49-67. Neither E-4031 nor 4-AP produced significant effects on KCNQ2/KvLR1 current. Similarly, both reagents do not inhibit KCNQ1/KvLQT1 currents. Yang *et al.* (1997), *Proc. Natl. Acad. Sci. USA* 94:4017-21.

TEA is a weak inhibitor of KCNQ1/KvLQT1 whereas clofilium is a strong inhibitor of KCNQ1/KvLQT1. Yang *et al.* (1997), *Proc. Natl. Acad. Sci. USA* 94:. Clofilium also inhibits cardiac I_{Kr} and I_{Ks} . Arena *et al.* (1988), *Molecular Pharmacology* 34: 60-66; Colatsky *et al.* (1990), *Circulation* 82: 2235-42. For KCNQ2/KvLR1, in contrast, clofilium had little effect whereas TEA inhibited the current by over 85% at a concentration of 1 mM.

The pharmacology of KCNQ3 was significantly different than that of KCNQ2 (Figure 18D). Clofilium (10 μ M) reduced KCNQ3 current by 30% from control but had little effect on KCNQ2. TEA, which strongly inhibited KCNQ2 at 1 mM, produced little inhibition of KCNQ3 at 5mM. CTX (100 nM), 4-AP (2 mM) and E-4031 (10 μ M) also had no effect on KCNQ3 current.

As can be seen from these results, the pharmacological properties of KCNQ3/KvLR2, KCNQ2/KvLR1 and KCNQ1/KvLQT1 are quite different.

KCNQ2 and KCNQ3 functionally interact

The overlapping expression pattern of KCNQ2 and KCNQ3 in different brain
5 regions (Figure 5), prompted us to test for functional interaction between the two
channels. Families of currents elicited by depolarizing voltage steps in oocytes
injected with KCNQ2 and KCNQ3 alone and together are shown in Figure 19A
through Figure 19C. Current amplitudes recorded from oocytes co-expressing the two
channels were 15-fold greater than in oocytes injected with each of the channels
10 individually. Peak current amplitudes at +30 mV for KCNQ2, KCNQ3 and
KCNQ2+KCNQ3 were 0.98 ± 0.09 (n=6), 0.98 ± 0.06 (n=5) and 14.2 ± 0.62 μ M (n=6),
respectively. Quantitatively similar results were obtained in 3 separate batches of
oocytes. The IV relationship shows that KCNQ2+KCNQ3 currents activated at
potentials positive to -60 mV and did not rectify, unlike KCNQ2 and particularly
15 KCNQ3, at positive voltages (Figure 19D). The reversal potential of tail currents
shifted by 57 mV per 10-fold change in external K^+ indicating that KCNQ2+KCNQ3
is nearly perfectly selective for K^+ (Figure 19E). KCNQ2+KCNQ3 current is weakly
sensitive to inhibition by 5 mM TEA and 10 μ M clofilium but not to 100 nM CTX or
2 mM 4-AP (Figure 19F). E-4031 (10 μ M) also did not inhibit KCNQ2+KCNQ3
20 current (not shown). These results suggest strongly that KCNQ2+KCNQ3 interact to
form a channel with properties distinct from either KCNQ2 or KCNQ3 channels
alone.

KCNE1 interacts with KCNQ2+KCNQ3 channels

The β subunit KCNE1 dramatically alters the amplitude and gating kinetics of
25 the KCNQ1 channel. Barhanin *et al.* (1996) *Nature* 384: 78-80; Sanguinetti *et al.*
(1996), *Nature* 384: 80-83; Yang *et al.* (1997) *Proc. Natl. Acad. Sci. USA* 94:4017-2;
Romey *et al.* (1997) *J. Biol. Chem.* 272:16713-16716. Because KCNQ2 and KCNQ3
are members of the same K^+ channel subfamily, we tested for an interaction between
KCNE1 and KCNQ2+KCNQ3 channels. Figure 20 shows currents elicited by 1 sec
30 depolarizing voltage steps in oocytes expressing KCNE1 alone (Figure 20A),

KCNQ2+KCNQ3 (Figure 20B), and KCNQ2+KCNQ3+KCNE1 (Figure 20C).

KCNE1 significantly attenuated KCNQ2+KCNQ3 current amplitude and slowed gating kinetics. Peak current amplitude at +30 mV was reduced by $62 \pm 6.0\%$ ($n=6$) in

oocytes co-expressing KCNE1. Activating currents were fitted to a bi-exponential

5 function to determine fast and slow time constants of activation. Fast and slow time constants for activation of KCNQ2+KCNQ3 current at +10 mV were 50.1 ± 3.4 ($n=6$) and 239.3 ± 17.5 ms ($n=6$), respectively; these were shifted to 124.7 ± 8.8 ($n=5$) and

680.7 ± 71.4 ms ($n=6$) when KCNE1 was injected together with KCNQ2+KCNQ3.

Similar results were obtained in more than 15 oocytes from each group in this and two
10 additional batches of oocytes. KCNE1 currents appear absent because of the duration (1 sec) of the voltage steps used and the scale at which the currents are shown.

However, as shown clearly in the inset in Figure 20A, 5 sec voltage steps elicited typical KCNE1 currents in the same oocyte. The effect of KCNE1 on gating kinetics is similar for KCNQ1 and KCNQ2+KCNQ3 channels. In contrast, KCNE1 augments

15 KCNQ1 current but inhibits KCNQ2+KCNQ3.

The results explain why mutations in either of two unlinked K^+ -channel encoding genes yield the same phenotype. BFNC-associated mutations in either KCNQ2 or KCNQ3 could cause a profound reduction in KCNQ2+KCNQ3 current amplitude. One study has shown that a BFNC-causing mutation resulting in an
20 nonfunctional, truncated KCNQ2 protein, failed to produce a dominant-negative inhibition of wild-type KCNQ2 channels expressed in oocytes. Biervert *et al.* (1998), *Science* 279:403-406. The present invention, demonstrating a synergistic interaction between KCNQ2 and KCNQ3, may provide a likely explanation for this finding. That is, mutations in KCNQ2 may only produce dominant-negative effects when co-
25 expressed with wild-type KCNQ3 channels, and vice versa.

Molecular genetics

Recent advances in molecular genetics has allowed us to correlate potassium channels with diseases in the nervous system. Most recently, and as discussed above, BFNC, a class of idiopathic generalized epilepsy, was recently

linked to mutations in KCNQ2 and KCNQ3. Biervert et al., supra; Charlier et al., supra; and Singh et al., supra. The identification and expression of human KCNQ2 and human KCNQ3 will allow us to investigate further correlations with BFNC and other potential human disease. The present invention will now permit those skilled in the art to identify modulators, e.g., activators, of KCNQ2 and/or KCNQ3.

Modulators of KCNQ2 and/or KCNQ3 may provide opportunity for treatment of disease, such as BFNC. Additionally, because human KCNQ2 and KCNQ3 are expressed highly in areas associated with learning and memory, modulators of KCNQ2 and/or KCNQ3 may also provide opportunity for pharmacological treatment of the memory loss associated with advanced age, Parkinson's disease or Alzheimer's disease.

Murine KvLR1

Starting with a brain expressed sequence tag (EST, public domain database) similar to the KvLQT1 gene, a novel potassium channel gene was cloned from a mouse brain library and functionally expressed. Figure 10A through Figure 10D shows the murine KCNQ2/KvLR1 gene (SEQ ID NO:5) encoding for a protein of 722 amino acids (SEQ ID NO:6) and a calculated molecular weight of 80.4 kDa. Hydropathy analysis (Figure 10E) illustrates the computer-generated topology of KvLR1 to have 6 membrane spanning domains and a pore domain typical of voltage-gated potassium channels.

The amino acid alignment of the murine KCNQ2/KvLR1 channel with the murine KCNQ1/KvLQT1 channel is shown in Figure 11. Overall, there is 40% identity between the two channels with 62.5% identity within the spanning and pore domains. Phylogenetic analysis suggests that the murine KCNQ2/KvLR1 gene to be a member of the KCNQ1/KvLQT1 gene family and to be distantly related to the HERG gene and other voltage-gated family members. Signature amino acid sequences characteristic of voltage-gated potassium channels are present within murine KCNQ2/KvLR1; a repeating arginine pattern is seen within the S4 spanning domain known as the voltage sensor, and a GYG sequence within the pore region. Further analysis of several 3' RACE clones indicate diversity past the S6 membrane

spanning domain. To date, two alternative splice exons, A and B, have been identified, the amino acid sequences of which are shown in Figure 12.

To determine tissue distribution of murine KCNQ2/KvLR1, a northern blot was performed with a probe from the murine KCNQ2/KvLR1 channel that did not contain the pore or voltage sensor regions. This sequence of the gene avoids possible cross-reactivity with other channels. The results, shown in Figure 13, indicate a highly abundant 8.2 kb message found only in the brain and not observed in peripheral tissues. Although not absolute, longer exposures of the northern blot did not indicate the presence of the message in the peripheral tissues indicated in Figure 5.

To obtain higher resolution of message localization within the brain, *in situ* hybridization was performed. Positive hybridization signal with an antisense riboprobe specific for a nonconserved region of the KCNQ2/KvLR1 gene is observed with a broad distribution throughout much of the rat brain. The mouse probe was 99% identical to the rat sequence. Robust signal, however, is observed with a more limited distribution in the following regions: piriform cortex, supraoptic nucleus, amygdala, hippocampus, including the CA1, 2, and 3 regions and the dentate gyrus, MO5 (motor nucleus of the brain stem trigeminal), facial nucleus, hypoglossal nucleus, inferior olivary nuclei, deep cerebellar nuclei, gigantocellular nuclei, lateral and medial vestibular nuclei, motor neurons of the spinal cord, and sensory neurons of the dorsal root ganglion. Moderate levels of hybridization signal are also observed in the cortex, septum, striatum, hypothalamus, thalamus, medial habenula, substantia nigra compacta, mammillary nuclei, lateral and medial geniculate, interfascicular nucleus, purkinje and granule cells of the cerebellum, parabrachial nuclei, dorsal and ventral cochlear nuclei, and other brain stem nuclei. A composite view of three regions is shown in Figure 14.

To test for functional expression, cRNA was prepared from the murine KCNQ2/KvLR1 gene and injected into *Xenopus* oocytes. In a two-electrode voltage clamp, a family of outward currents were generated in murine KCNQ2/KvLR1 cRNA-injected oocytes ($n > 20$). After a minimum of 48 hours, currents qualitatively and quantitatively different than native currents generated with identical protocols in water injected or uninjected control cells (representing Ca^{2+} -activated chloride

currents and other native currents) (Figure 15). The murine KCNQ2/KvLR1-mediated currents were blocked by 1 mM TEA. Similar currents were obtained from CHO cells stably expressing murine KCNQ2 and recorded using patch-clamp techniques. Single channel conductances were estimated to be 24-30 pS in symmetrical 140 mM potassium. (Figure 22).

To determine if murine KCNQ2/KvLR1 has similar pharmacology to I_{Ks} and I_{Kr} currents in cardiac myocytes, clofilium was tested on oocytes expressing murine KCNQ2. At 20 μ M, clofilium was shown to partially block the murine KCNQ2-mediated currents. Other specific K^+ channel blocking toxins, including iberiotoxin, α -dendrotoxin and charybdotoxin, had no significant effect on murine KCNQ2-mediated currents.

Materials and Methods

Human KCNQ2

Molecular cloning and expression of human KCNQ2 (human KvLR1) and human KCNQ3 (human KvLR2)

5' RACE PCR was performed by amplifying human brain or fetal brain cDNA libraries or Marathon-Ready cDNAs (Clontech) using primers derived from the KvLQT1-related EST sequences (EST# yn72g11, yo31c08, ys93a07 (sequences can be found in Genbank database)) (Figure 1). PCR products were gel-purified, subcloned and sequenced. Random-primed 32 P-labelled DNA probes containing specific regions of KCNQ2 or KCNQ3 sequence were used for screening of cDNA libraries and Northern blot analysis using standard protocol. For example, KCNQ2 Probe I (Figure 1) was used for Northern blot analysis; Probe II (Figure 1) was used for screening human brain cDNA libraries according to standard protocols.

The Gene Trapper experiment was performed using the protocol as described in the Manufacturer's manual (LifeTechnologies). The composite full-length human KCNQ2 and human KCNQ3 cDNA clones were obtained by restriction enzyme digestion and ligation of overlapping cDNA clones. The full-length cDNAs were subcloned into a Xenopus expression vector, derived from pSP64T plasmid.

Capped cRNA for microinjection was synthesized using mMESSAGE mMACHINE Kit (Ambion).

For detection of expression of KCNQ2 as shown in Figures 9A and 9B, tissue processing, histological analyses and *in situ* hybridization analyses were performed essentially as described in Fagan *et al.* (1996), *J. Neurosci.* 16 (19): 6208-18.

Electrophysiological and pharmacological characterization of KCNQ2 and KCNQ3

Stage V and VI *Xenopus laevis* oocytes were defolliculated with collagenase treatment and injected with cRNAs, as described in Yang *et al.*, *supra*. Currents were recorded at room temperature using the two-microelectrode voltage clamp (Dagan TEV-200) technique between 3-5 days after injection of KCNQ2 (15 ng), KCNQ3 (15 ng), or KCNE1 (2 ng) cRNA alone or in combination. Microelectrodes (0.8 to 1.5 M Ω) were filled with 3 M KCl. Bath solution contained (in mM): 96 NaCl, 2 KCl, 0.4-1.8 CaCl₂, 1-2 MgCl₂ and 5 HEPES (pH 7.5). KCl was varied in some experiments by equimolar substitution with NaCl.

K⁺ selectivity was assessed by determining the dependence of tail current reversal potential on the external K⁺ concentration. Tail currents were elicited at potentials of -110 to +10 mV following a voltage step to +20 mV while the external K⁺ concentration was varied between 2, 10, 40, and 98 mM. Current reversal potential under each condition was determined for each oocyte by measuring the zero intercept from a plot of tail current amplitude vs test potential.

Axoclamp (Axon Instruments) was used for generating voltage clamp commands and acquiring data and Axograph 3.0 (Axon Instruments) was used for data analysis. All data was sampled at rates at least two times the low pass filter rate. Experiments were performed at 22-25 °C. Clofilum was obtained from RBI Biochemicals and 4-aminopyridine (4-AP), TEA and charybdotoxin were obtained from Sigma Chemical Co. E-4031 was synthesized from information published by Esai Research Laboratories.

Murine KvLR1

Probe preparation and library screening

A unique expressed sequence tag (EST) was identified from the public database that has similarity to the KvLQT gene. Oligonucleotide primers were synthesized from the EST sequence for PCR experiments. The forward primer (SEQ. ID. NO.: 15) was

5'-GAG TAT GAG AAG AGC TCG GA-3'

and reverse primer (SEQ. ID. NO.: 16) was

5'-CAG ATG TGG CAA AGA CGT TGC-3'.

10 Rat brain polyA⁺ RNA was reverse-transcribed with random hexamers and amplified by PCR [60 sec 94 °C, 90 sec 55 °C, 120 sec 72 °C, 30 cycles] with the above primers. A 240 bp DNA fragment of rat KCNQ2/KvLR1 was isolated by gel electrophoresis and subcloned into pCRII (InVitrogen). The 240 bp DNA fragment was random-prime labeled with ³²P-dCTP and used as a probe to screen a mouse
15 brain pcDNA1 plasmid library (Clontech, Palo Alto, CA). Overall, 2x10⁵ colonies were screened using standard filter lift protocols. The filters were hybridized overnight in 50% formamide, 2X PIPES and 1% SDS at 42 °C and washed 1x in 1X SSC then 3x 20 minutes in 0.1x SSC, 0.1% SDS at 53 °C. Filters were exposed overnight at -70 °C. Only one positive colony was identified and replated until
20 purified. Clone mbr 26.1, designated murine KvLR1, was sequenced on both strands by dideoxy termination reactions.

Northern Blots

Northern blots were performed with the mouse multiple tissue blot (Clontech) according to the manufacturer's instructions. Briefly, the blot was prehybridized at
25 68°C with ExpressHyb solution for 30 minutes. A DNA fragment was isolated from the murine KvLR1 coding region by the restriction enzyme PvuII, which eliminated the pore and voltage sensor consensus sequences, and random-prime labeled with ³²P-dCTP, denatured at 100°C for 5 minutes, chilled on ice and added to fresh ExpressHyb before addition to the northern blot. The blot was incubated for 60
30 minutes at 68°C with continuous shaking. The blot was washed 2X at 50°C in 0.1X SSC and 0.1% SDS. The blot was wrapped in saran wrap and exposed to x-ray film

overnight at room temperature. The same protocol was used for the actin probe provided with the blot.

In situ hybridization

Frozen sections cut at intervals of 225 μ m through the entire adult rat brain were fixed by immersion (without thawing) into ice cold 10% formaldehyde in PBS for 20 minutes and rinsed with PBS. Fixed sections of rat DRG were treated with 0.5% Triton X-100 in 0.1 M Tris, pH 8.0, and 0.05 M EDTA for 30 minutes and rinsed for 3 minutes in 0.1 M Tris, pH 8.0, and 0.05 M EDTA. The tissue was then treated with 0.1 M TEA, pH 8.0, plus 0.25% acetic anhydride for 10 minutes at room temperature, rinsed (3 X) in 2X SSC, dehydrated through a series of alcohols, delipidated in chloroform, and air dried.

Riboprobes were synthesized using the Promega Riboprobe Transcription System II with 250 μ Ci 35 S-UTP and 250 μ Ci 35 S-CTP in a total reaction volume of 10 μ L. Unlabeled UTP and CTP were added at 25 μ M each and ATP and GTP at 500 μ M each. The murine KCNQ2/KvLR1 plasmid (nts 552-1125 subcloned into pBluescript II) was linearized with Sac I and transcribed using T3 RNA polymerase, and with BamHI and transcribed using SP6 RNA polymerase to generate anti-sense and sense probes, respectively. One μ g of linearized plasmid was added for each reaction. The riboprobes were purified by phenol:chloroform extraction and two ethanol precipitations using ammonium acetate. The dried tissue sections were hybridized with 1×10^7 cpm/ml riboprobe in hybridization buffer (50% formamide, 0.3 M NaCl, 10 mM Tris, 1 mM EDTA, 1X Denhardt's solution, 10% dextran sulfate, 500 μ g/ml tRNA and 10 mM DTT) overnight at 55°C. The hybridization solution was removed by rinsing 4 times in 4X SSC, 5 minutes for each wash. The sections were incubated in 0.02 mg/ml RNase, 0.5 M NaCl, 10 mM Tris, pH 8.0, and 1 mM EDTA for 30 minutes at 37°C, then washed in 2X SSC, 1X SSC and 0.5X SSC, all containing 1 mM DTT, for 10 minutes per wash at room temperature. The tissues were incubated in 0.1X SSC, 1 mM DTT for 30 minutes at 55°C, then rinsed briefly in 0.1X SSC and 1 mM DTT at room temperature, dehydrated, and air dried. The dried sections were exposed to XOMAT film (Kodak, Rochester, NY), then were

dipped in NTB2 emulsion (Kodak, Rochester, NY) to determine the cellular localization of each mRNA.

Expression and Recording in Oocytes

The murine KCNQ2/KvLR1 cDNAs were linearized with the restriction enzyme NotI and in vitro transcribed using the mMessage mMachine T7 RNA polymerase kit according to the manufacturer's instructions (Ambion, Austin, TX). The cRNAs were solubilized in RNase-free water, and stored at -70°C at a concentration of $1.0\text{ }\mu\text{g}/\mu\text{l}$. Frog oocytes were prepared and injected using standard techniques (Colman, 1984). In murine KvLR1 expression experiments, each oocyte was injected with approximately 35-40 nl of the cRNA. Following injection, oocytes were maintained at 17°C in ND96 medium consisting of (in mM): NaCl, 90; KCl, 1.0; CaCl_2 , 1.0; MgCl_2 , 1.0; HEPES, 5.0; pH 7.5. Horse serum and penicillin/streptomycin, both 5% of final volume, were added as supplements to the incubation medium. Electrophysiological recording commenced 2-6 days following cRNA injection. Prior to the start of an experiment oocytes were placed in a recording chamber and incubated in Modified Barth's Solution (MBS) consisting of (in mM): NaCl, 88; NaHCO_3 , 2.4; KCl, 1.0; HEPES, 10; MgSO_4 , 0.82; $\text{Ca}(\text{NO}_3)_2$, 0.33; CaCl_2 , 0.41; pH 7.5. Oocytes were impaled with electrodes ($1\text{-}2\text{ M}\Omega$) and standard 2-electrode voltage clamp techniques were employed to record whole-cell membrane currents (Stuhmer, 1992; TEC 200, Dagan Instruments). Voltage-clamp protocols typically consisted of a series of voltage steps 100-500 ms duration, in +10 mV steps from a holding potential of -60 mV to -90 mV to a maximal potential of +40 mV to +50 mV; records were digitized at 5 kHz and stored on a computer using pClamp 6.0 software (Axon Instruments), and analyzed using ClampFit or AxoGraph software (Axon Instruments).

Expression and Recording in CHO cells

Patch clamp recordings were obtained from CHO cells that transiently or stably expressed murine KCNQ2 channels. Electrodes were prepared using a PC-84 Sachs-Flaming pipette puller (Sutter Instruments) and fire-polished to a final tip resistance of 3-5 $\text{M}\Omega$. Pipettes were filled with a solution that consisted of (in mM)

KCl (140), MOPS (20), K₂EGTA (1.0), CaCl₂ (0.89), pH 7.2. The pipette solution sometimes contained MgCl₂ (1.0) to aid in seal formation. Cells were grown on poly-D-lysine coated coverslips, and pieces of the coverslips containing CHO cells were placed into a chamber on an inverted microscope for recording. Prior to recording, and during seal formation, cells were bathed in an external solution consisting of (in mM) NaCl (145), KCl (3), CaCl₂ (2.5), MgCl₂ (1.0), HEPES (10), pH 7.4. Electrodes were lowered to the surface of cells under visual inspection; following gigaseal formation inside-out membrane patches were excised into an internal solution consisting of (in mM) KCl (140), MOPS (20), K₂EGTA (1.0), CaCl₂ (0.89), pH 7.2. All recordings were made under symmetrical K⁺ conditions. Following patch excision continuous and step-protocol voltage-clamp recordings were obtained, and analyses performed, using an AxoPatch 200B Patch Clamp amplifier and pClamp software (Axon Instruments). Results are shown in Figure 22.

Although the present invention has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims.

What is claimed is:

1. An isolated nucleic acid molecule encoding a polypeptide comprising all or a portion of a KCNQ protein, wherein said KCNQ protein is selected from the group consisting of human KCNQ2 protein, human KCNQ3 protein, murine KCNQ2 protein, and rat KCNQ2 protein.
2. The nucleic acid molecule of claim 1 wherein said human KCNQ2 protein comprises the amino acid sequence as shown in SEQ ID NO:4.
3. The nucleic acid molecule of claim 1 wherein said human KCNQ3 protein comprises the amino acid sequence as shown in SEQ ID NO:18.
4. The nucleic acid molecule of claim 1 wherein said murine KCNQ2 protein comprises the amino acid sequence as shown in SEQ ID NO:6.
5. The nucleic acid molecule of claim 1 selected from the group consisting of: (a) all or a portion of a nucleic acid sequence as shown in SEQ ID NO:3; (b) the complement of (a); and (c) variations of (a) due to degeneracy in the genetic code.
6. The nucleic acid molecule of claim 1 selected from the group consisting of: (a) all or a portion of a nucleic acid sequence as shown in SEQ ID NO:17; (b) the complement of (a); and (c) variations of (a) due to degeneracy in the genetic code.
7. The nucleic acid molecule of claim 1 selected from the group consisting of: (a) all or a portion of a nucleic acid sequence as shown in SEQ ID NO:5; (b) the complement of (a); and (c) variations of (a) due to degeneracy in the genetic code.
8. A vector comprising the nucleic acid molecule of claim 1.
9. A vector comprising the nucleic acid molecule of claim 2.
10. A vector comprising the nucleic acid molecule of claim 3.
11. A vector comprising the nucleic acid molecule of claim 5.
12. A vector comprising the nucleic acid molecule of claim 6.
13. A prokaryotic or eukaryotic host cell comprising the vector of claim 8.
14. A prokaryotic or eukaryotic host cell comprising the vector of claim 9.
15. A prokaryotic or eukaryotic host cell comprising the vector of claim 10.
16. A prokaryotic or eukaryotic host cell comprising the vector of claim 11.
17. A prokaryotic or eukaryotic host cell comprising the vector of claim 12.

18. An isolated KCNQ protein or polypeptide comprising all or a portion of an amino acid sequence selected from the group consisting of human KCNQ2 as shown in SEQ ID NO:4, human KCNQ3 as shown in SEQ ID NO:18, murine KCNQ2 as shown in SEQ ID NO:6, and rat KCNQ2 as shown in SEQ ID NO:8.
- 5 19. An isolated nucleic acid molecule selected from the group consisting of: (a) a nucleotide sequence that exhibits at least 80% sequence identity to the nucleotide sequence as shown in SEQ ID NO:3; (b) a nucleotide sequence that exhibits at least 80% sequence identity to the nucleotide sequence as shown in SEQ ID NO:17; and (c) a nucleotide sequence that exhibits at least 80% sequence identity to the nucleotide sequence as shown in SEQ ID NO:5.
- 10 20. A method of screening for a compound that is capable of modulating the activity of a KCNQ protein, comprising the steps of:
- (a) providing a host cell of claim 13;
 - (b) determining the activity of said KCNQ protein in the absence of said
 - 15 compound;
 - (c) contacting the cell with said compound; and
 - (d) determining the activity of said KCNQ protein in the presence of said compound,
- 20 wherein a difference between the activity of said KCNQ protein in the presence of said compound and in the absence of said compound indicates a modulating compound.
21. An antibody specific for the KCNQ protein of claim 18.
22. The antibody of claim 21, wherein said antibody is a monoclonal antibody.

1 / 42




FIG. 1

2/42

CCCCGCGCTCCGCCCCGCTGAGCCTGAGCCCCACCCGGGGCGCCTCCCGCCAGGCACCATGGTGCAGAAGTCG
GGGGGCGCGAGGCGGGGGCGACTCGGACTCGGGCTGGGCCCGCGGAGGGCGGTCCGTGGTACCACGTCTTCAGC
M V Q K S

100

150

CGCAACGGCGGGCGTATACCCGGGCCGAGCGGGGAGAAGAAGCTGAAGGTGGGCTTCGTGGGGCTGGACCCCGGC
GCGTTGCCGCGCATATGGGGCGGGCTCGCCCTCTTCTTCGACTTCCACCCGAAGCACCCGACCTGGGGCCG
R N G G V Y P G P S G E K K L K V G F V G L D P G>

200

GCGCCCGACTCCACCCGGGACGGGGCGCTGCTGATCGCCGGCTCCGAGGCCCCCAAGCGCGGCAGCATCCTCAGC
CGCGGGCTGAGGTGGGCCCTGCCCCGCGAGCTAGCGGCCGAGGCTCCGGGGGTTCCGCGCGTCTGAGGAGTCG
A P D S T R D G A L L I A G S E A P K R G S I L S

250

300

AAACCTCGCGGGGCGCGGGCGCCGGGAAGCCCCCAAGCGCAACGCCTTCTACCGCAAGCTGCAGAATTTC
TTTGAGCGCGCCCGCGCGCCCGCGGCCCTTCGGGGGTTTCGCGTTGCGGAAGATGGCGTTCGACGTCTTAAAG
K P R A G G A G A G K P P K R N A F Y R K L Q N F>

350

CTCTACAACGTGCTGGAGCGGCCGCGCGGCTGGGCGTTCATCTACCACGCCTACGTGTTCTCCTGGTTTTCTCC
GAGATGTTGCACGACCTCGCCGGCGCGCCGACCCGCAACTAGATGGTGCGGATGCACAAGGAGGACCAAAAGAGG
L Y N V L E R P R G W A F I Y H A Y V F L L V F S

400

450

TGCCTCGTGCTGTCTGTGTTTTCCACCATCAAGGAGTATGAGAAGAGCTCGGAGGGGGCCCTCTACATCCTGGAA
ACGGAGCACGACAGACACAAAAGGTGGTAGTTCCTCATACTCTTCTCGAGCCTCCCCGGGAGATGTAGGACCTT
C L V L S V F S T I K E Y E K S S E G A L Y I L E>

500

ATCGTGAATATCGTGGTGTGTTTGGCGTGGAAGTACTTCGTGCGGATCTGGGCCGAGGCTGCTGCTGCCGGTACCGT
TAGCACTGATAGCACCAAAACCGCACCTCATGAAGCACGCTAGACCCGGCGTCCGACGACGACGGCCATGGCA
I V T I V V F G V E Y F V R I W A A G C C C R Y R

550

600

GGCTGGAGGGGGCGGCTCAAGTTTGCCGGAAACCGTTCTGTGTGATTGACATCATGGTGCTCATCGCCTCCATT
CCGACCTCCCCCGCCGAGTTCAAACGGGCTTTGGCAAGACACACTAAGTGTAGTACCACGAGTAGCGGAGGTAA
G W R G R L K F A R K P F C V I D I M V L I A S I>

FIG. 2A

SUBSTITUTE SHEET (RULE 26)

3/42

650

GCGGTGCTGGCCGCCGGCTCCAGGGCAACGTCTTTGCCACATCTGCGCTCCGGAGCCTGCGCTTCCTGCAGATT
CGCCACGACCGGGCGGCCGAGGGTCCCGTTGCAGAAACGGTGTAGACGCGAGGCCCTCGGACGCGAAGGACGTCTAA
A V L A A G S Q G N V F A T S A L R S L R F L Q I

700

750

CTGCGGATGATCCGCATGGACCGGCGGGGAGGCACCTGGAAGCTGCTGGGCTCTGTGGTCTATGCCCACAGCAAG
GACGCCTACTAGGCGTACCTGGCCGCCCTCCGTGGACCTTCGACGACCCGAGACACCAGATACGGGTGTCTTC
L R M I R M D R R G G T W K L L G S V V Y A H S K>

800

GAGCTGGTCACTGCCTGGTACATCGGCTTCCTTTGTCTCATCCTGGCCTCGTTCTGGTGTACTTGGCAGAGAAG
CTCGACCAGTGACGGACCATGTAGCCGAAGGAAACAGAGTAGGACCGGAGCAAGGACCACATGAACCGTCTCTTC
E L V T A W Y I G F L C L I L A S F L V Y L A E K

850

900

GGGGAGAACGACCACTTTGACACCTACGCGGATGCACTCTGGTGGGGCCTGATCACGCTGACCACCATTGGCTAC
CCCCTCTTGCTGGTGAAACTGTGGATGCGCCTACGTGAGACCACCCCGGACTAGTGCGACTGGTGGTAACCGATG
G E N D H F D T Y A D A L W W G L I T L T T I G Y>

950

GGGGACAAGTACCCCCAGACCTGGAACGGCAGGCTCCTTGCGGCAACCTTCACCCTCATCGGTGTCTCCTTCTTC
CCCCTGTTTCATGGGGGTCTGGACCTTGCCGTCCGAGGAACGCCGTTGGAAGTGGGAGTAGCCACAGAGGAAGAAG
G D K Y P Q T W N G R L L A A T F T L I G V S F F

1000

1050

GCGCTGCCTGCAGGCATCTTGGGGTCTGGGTTTGCCTGAAGGTTCAAGGAGCAGCACAGGCAGAAGCACTTTGAG
CGCGACGGACGTCCGTAGAACCCAGACCCAAACGGGACTTCCAAGTCTCGTCTGTCGTCCTTCGTGAAACTC
A L P A G I L G S G F A L K V Q E Q H R Q K H F E>

1100

AAGAGGCGGAACCCGGCAGCAGGCCTGATCCAGTCGGCCTGGAGATTTTACGCCACCAACCTCTCGCGCACAGAC
TTCTCCGCCTTGGGCCGTGCTCCGGAAGTACGCGGACCTCTAAATGCGGTGGTTGGAGAGCGCGTGTCTG
K R R N P A A G L I Q S A W R F Y A T N L S R T D

1150

1200

CTGCACTCCACGTGGCAGTACTACGAGCGAACGGTCACCGTGCCCATGTACAGTTGCGAAACTCAAACCTACGGG
GACGTGAGGTGCACCGTCATGCTCGCTTGCCAGTGGCACGGGTACATGTCAAGCGTTTGAGTTGGATGCCC
L H S T W Q Y Y E R T V T V P M Y S S Q T Q T Y G>

FIG. 2B

SUBSTITUTE SHEET (RULE 26)

4 / 42

1250

GCCTCCAGACTTATCCCCCGCTGAACCAGCTGGAGCTGCTGAGAAACCTCAAGAGTAAATCTGGACTCGCTTTC
CGGAGGTCTGAATAGGGGGGCGACTTGGTCGACCTCGACGACTCTTTGGAGTTCTCATTTAGACCTGAGCGAAAG
A S R L I P P L N Q L E L L R N L K S K S G L A F

1300

1350

AGGAAGGACCCCCCGCCGGAGCCGTCTCCAAGTAAAGGCAGCCCGTGCAGAGGGCCCTGTGTGGATGCTGCCCC
TCCTTCTGGGGGGCGGCCTCGGCAGAGGTTCAATTTCCGTGGGGCAGCTCTCCGGGGACACACCTACGACGGGG
R K D P P P E P S P S K G S P C R G P L C G C C P>

1400

GGACGCTCTAGCCAGAAGGTCAGTTTGAAAGATCGTGTCTTCTCCAGCCCCGAGGCGTGGCTGCCAAGGGGAAG
CCTGCGAGATCGGTCTTCCAGTCAAACCTTTCTAGCACAGAAGAGGTCGGGGGCTCCGCACCGACGGTTCCCCTTC
G R S S Q K V S L K D R V F S S P R G V A A K G K

1450

1500

GGGTCCCCGCAGGCCCAGACTGTGAGGCGGTCAACCAGCGCCGACCAGAGCCTCGAGGACAGCCCCAGCAAGGTG
CCCAGGGGCGTCCGGGTCTGACACTCCGCCAGTGGGTGCGGGCTGGTCTCGGAGCTCCTGTGCGGGGTCGTTCCAC
G S P Q A Q T V R R S P S A D Q S L E D S P S K V>

1550

CCCAAGAGCTGGAGCTTCGGGGACCGCAGCCGGGCACGCCAGGCTTTCGCGATCAAGGGTGCGGGCGTCACGGCAG
GGGTTCTCGACCTCGAAGCCCCTGGCGTGGGCCCGTGCGGTCCGAAAGGCGTAGTTCCACGCCGAGTGCCGTC
P K S W S F G D R S R A R Q A F R I K G A A S R Q

1600

1650

AACTCAGAAGCAAGCCTCCCCGGAGAGGACATTGTGGATGACAAGAGCTGCCCTGCGAGTTTGTGACCGAGGAC
TTGAGTCTTCGTTGAGGGGCTCTCCTGTAACACCTACTGTTCTCGACGGGGACGCTCAAACACTGGCTCCTG
N S E A S L P G E D I V D D K S C P C E F V T E D>

FIG. 2C

SUBSTITUTE SHEET (RULE 26)

5/42

1700

CTGACCCCGGGCCTCAAAGTCAGCATCAGAGCCGTGTGTGTCATGCGGTTCTGGTGTCCAAGCGGAAGTTCAAG
GACTGGGGCCCGGAGTTTCAGTCGTAGTCTCGGCACACACAGTACGCCAAGGACCACAGGTTTCGCCTTCAAGTTC
L T P G L K V S I R A V C V M R F L V S K R K F K

1750

1800

GAGAGCCTGCGGCCCTACGACGTGATGGACGTCATCGAGCAGTACTCAGCCGGCCACCTGGACATGCTGTCCCGA
CTCTCGGACGCCGGGATGCTGCACTACCTGCAGTAGCTCGTCATGAGTCGGCCGGTGGACCTGTACGACAGGGCT
E S L R P Y D V M D V I E Q Y S A G H L D M L S R>

1850

ATTAAGAGCCTGCAGTCCAGAGTGGACCAGATCGTGGGGCGGGGCCAGCGATCACGGACAAGGACCGCACCAAG
TAATTCTCGGACGTCAGGTCTCACTGGTCTAGCACCCCCGCCCCGGGTCGCTAGTGCTGTTCTGGCGTGGTTCT
I K S L Q S R V D Q I V G R G P A I T D K D R T K

1900

1950

GGCCCGGCCGAGGCGGAGCTGCCCGAGGACCCAGCATGATGGGACGGCTCGGGAAGGTGGAGAAGCAGGTCTTG
CCGGGCCGGCTCCGCCTCGACGGGCTCCTGGGGTCTACTACCCTGCCGAGCCCTTCCACCTCTTCGTCCAGAAC
G P A E A E L P E D P S M M G R L G K V E K Q V L>

2000

TCCATGGAGAAGAAGCTGGACTTCCTGGTGAATATCTACATGCAGCGGATGGGCATCCCCCGACAGAGACCGAG
AGGTACCTCTTCTTCGACCTGAAGGACCACTTATAGATGTACGTCGCCTACCCGTAGGGGGGCTGTCTCTGGCTC
S M E K K L D F L V N I Y M Q R M G I P P T E T E

2050

2100

GCCTACTTTGGGGCCAAAGAGCCGGAGCCGGCGCCGCGTACCACAGCCCGGAAGACAGCCGGGAGCATGTGAC
CGGATGAAACCCCGGTTTCTCGGCCTCGGCCGCGGCGCATGGTGTGCGGCCCTTCTGTGCGCCCTCGTACAGCTG
A Y F G A K E P E P A P P Y H S P E D S R E H V D>

FIG. 2D

SUBSTITUTE SHEET (RULE 26)

6 / 42

2150

AGGCACGGCTGCATTGTCAAGATCGTGCGCTCCAGCAGCTCCACGGGCCAGAAGAAGCTTCTCGGCGCCCCGGCC
TCCGTGCCGACGTAACAGTTCTAGCACGCGAGGTCTGTCGAGGTGCCCGGTCTTCTTGAAGAGCCGCGGGGGCCGG
R H G C I V K I V R S S S S T G Q K N F S A P P A

2200

2250

GCGCCCCCTGTCCAGTGTCCGCCCTCCACCTCCTGGCAGCCACAGAGCCACCCGCGCCAGGGCCACGGCACCTCC
CGCGGGGGACAGGTACAGGGCGGGAGGTGGAGGACCGTCGGTGTCTCGGTGGGCGCGGTCCCGGTGCCGTGGAGG
A P P V Q C P P S T S W Q P Q S H P R Q G H G T S>

2300

CCCGTGGGGGACCACGGCTCCCTGGTGCGCATCCCGCCGCCGCTGCCACGAGCGGTCTGCTGTCGCTACGGC
GGGACCCCCCTGGTGCCGAGGGACCACGCGTAGGGCGGCGGGACGGGTGCTCGCCAGCGACAGGCGGATGCCG
P V G D H G S L V R I P P P P A H E R S L S A Y G

2350

2400

GGGGGCAACCGCGCCAGCATGGAGTTCTGCGGCAGGAGGACACCCCGGGCTGCAGGCCCCCGAGGGGACCTG
CCCCCGTTGGCGCGGTCTACCTCAAGGACGCCGTCTCTGTGGGGCCCGACGTCCGGGGGGCTCCCTGGGAC
G G N R A S M E F L R Q E D T P G C R P P E G T L>

2450

CGGGACAGCGACACGTCCATCTCCATCCCGTCCGTGGACCACGAGGAGCTGGAGCGTTCTTCAGCGGCTTCAGC
GCCCTGTGCTGTGCAGGTAGAGGTAGGGCAGGCACCTGGTGCTCTCTGACCTCGCAAGGAAGTCGCCGAAGTCG
R D S D T S I S I P S V D H E E L E R S F S G F S

2500

2550

ATCTCCAGTCCAAGGAGAACCTGGATGCTCTCAACAGCTGCTACGCGGCCGTGGCGCCTTGTGCCAAAGTCAGG
TAGAGGGTCAGGTTCTCTTGGACCTACGAGAGTTGTGACGATGCGCCGGCACCGCGGAACACGGTTTCAGTCC
I S Q S K E N L D A L N S C Y A A V A P C A K V R>

2600

CCCTACATTGCGGAGGGAGAGTCAGACACCGACTCCGACCTCTGTACCCCGTGGGGCCCCCGCCACGCTCGGCC
GGGATGTAACGCCTCCCTCTCAGTCTGTGGCTGAGGCTGGAGACATGGGGCACGCCCGGGGGCGGTGCGAGCCGG
P Y I A E G E S D T D S D L C T P C G P P P R S A

2650

2700

ACCGGCGAGGGTCCCTTTGGTGACGTGGGCTGGGCGGGGCCAGGAAGTGAGGCGGCGCTGGGCCAGTGGACCCG
TGGCCGCTCCAGGGAAACCACTGCACCCGACCCGGCCGGGTCTTCACTCCGCCGCGACCCGGTCACCTGGG
T G E G P F G D V G W A G P R K>

FIG. 2E

SUBSTITUTE SHEET (RULE 26)

7 / 42

2750

CCCGCGGCCCTCCTCAGCACGGTGCCTCCGAGGTTTTGAGGCGGGAACCCTTTGGGGCCCTTTTCTTACAGTAAC
GGGCGCCGGGAGGAGTCGTGCCACGGAGGCTCCAAACTCCGCCCTTGGGAAACCCGGGAAAAGAATGTCATTG

2800

2850

TGAGTGTGGCGGGAAGGGTGGGCCCTGGAGGGGCCCATGTGGGCTGAAGGATGGGGGCTCCTGGCAGTGACCTTT
ACTCACACCGCCCTTCCACCCGGGACCTCCCCGGGTACACCCGACTTCTACCCCGAGGACCGTCACTGGAAA

2900

TACAAAAGTTATTTTCCAACAGGGGCTGGAGGGCTGGGCAGGGCCCTGTGGCTCCAGGAGCAGCGTGCAGGAGCA
ATGTTTTCAATAAAAGGTTGTCCCCGACCTCCCGACCCGTCCCGGGACACCGAGGTCTCGTCGCACGTCTCGT

2950

3000

AGGCTGCCCTGTCCACTCTGCTCAGGGCCGCGGCCGACATCAGCCCGGTGTGAGGAGGGGCGGGAGTGATGACGG
TCCGACGGGACAGTTGAGACGAGTCCCGGCGCCGGCTGTAGTCGGGCCACACTCTCCCCGCCCTCACTACTGCC

3050

GGTGTGGCCAGCGTGGCAACAGGCGGGGGTTGTTTCAGCCGAGCCAGGGGAGGCACAAAGGGCAGGCCTGTTC
CCACAACGGTCGCACCGTTGTCCGCCCCCAACAAAGTCGGCTCGGGTCCCTCCGTGTTTCCCGTCCGGACAAG

3100

3150

CCTGAGGACCTGCGCAAAGGGCGGGCCTGTTTGGTGAGGACCTGCGGCCTTGGGTCCCGGTGGGGTTTCCGGGCA
GGACTCCTGGACGCGTTTCCCGCCCGGACAAACCACTCTGGACGCGGAACCCAGGGCCACCCCAAAGGCCCGT

3200

GCTACAGGCGGGTGTGGCCGGCCGCTGTGCGTGGCCTCTGCCTTACACCTGACCTGCCCCGGCGGGCTTTCCTGT
CGATGTCCGCCACACCGGCCGGCGACACGCACCGGAGACGGAAGTGTGGACTGGACGGGCGGCCGAAAGGACA

3250

TCCCCACCTCAGGGGCGCCCAAATACAGAGCTATTGTTGGCGTCTTAAAAAAAAAAAAAAAAA
AGGGGTGGAGTCCCCGCGGGTTATGTCTCGATAACCAACCGCAGAATTTTTTTTTTTTTT

FIG. 2F

SUBSTITUTE SHEET (RULE 26)

KVLQT1	55	MAAASSPPRAERKRWGRLPGARRGSAGLAKKCPFSLEAEGGPAGGALYAPIA	
KVLR1	28	MVQKSRNGGVYPGPSGEKKLKVG FVGLD	
KVLQT1	130	PGAPGPAPPAS--PAAPAAPVASDLGPRPPVSLDPRVSIYSTRRPVLARTHVQGRVYNFLERPTGWKCFVYHFAVF	
KVLR1	100	PGAPDSTRDGALLIAGSEAPKRGSI--SKPRAG-GAGAGK-PPKRNAFYR-KLQNFLYNVLERPRGWA-FIYHAYVF	
		S1	S2
KVLQT1	207	LIVLVCLIFSVLSTIEQYAAALATGTLFWMEIVLVVFFGTEYVVRLLWSAGCRSKYVGLWGRRLRFARKPISIIDLIVVV	S3
KVLR1	177	LLVFSCLVLSVFSTIKEYESSEGALYILEIVTIVVFGVEYFVRIWAAGCCCRYRGWRGRLLKFARKPFCVIDIMVLI	
		S4	S5
KVLQT1	284	ASMVVLGVGSKGVFATSIRGIRFLQILRMLHVDROGGTWRLLGSVVFIHRQELITTLYIGFLGLIFSSYFVYLAE	
KVLR1	254	ASIAVLAAGSQGNVVFATSALRSLRFLQILRMIRMDRRGGTWKLLGSVVYAHSKELVTAWYIGFLCLILASFLVYLAE	
		Pore	S6
KVLQT1	361	KDAVNESGRVEFGSYADALWWGVVTTTIGYGDKVPQTWVGKTIASCFSVFAISFFALPAGILGSGFALKVQKQKQKQ	
KVLR1	326	K---GENDH---FDTYADALWWGLITLTITIGYGDKVPQTWNGRLLAATFTLIGVSFFALPAGILGSGFALKVQEQHRQ	
KVLQT1	430	KHFNRIQIPAAASLIQTAWRCYAAE--NPD-SSTWKIYIRKAPRSHTLLSPSPKPKKSVVKKKKFKLDRKNG//	
KVLR1	398	KHFEKRRNPAAGLIQSAWRFYATNLSTRDLHSTWQYERTVTVPVMS-SQTQTYGASRLIPPLNQLELRNL//	

FIG. 3

55

MAAASSPPRAERKRWGWGRLPGARRGSAGLAKKCPFSLELAEGGPAGGALYAPIA

KvLQT1

29

PAGGDAAAAGDEERKVGLAPGDVEQVTLA

KvLR2

130

PGAPGPAPPAS--PAAAPAPPVADLGERPPVSLDPRVSIYSTRRPVLARTHVQGRVYNFLERPTGWKCFVYHFAVF

KvLQT1

103

LGA-GADKDGTLLEGGGRDEGQRRTPQIGILLAKTPLSRPVKRNNAKYR-RIQTLYDALERPRGWALL-YHALVF

KvLR2

S3

S2

S1

207

LIVLVCLIFSLSLSTIEQYAAALATGTLFWMEIVLVVFFGTEYVVRWLSAGCRSKYVGLWGRRLRFARKPISIIDLIVVV

KvLQT1

180

LIVLGCLILAVLTTFFKEYETVSGDWLLELLETFATFIFGAEFALRIWAAGCCCRYKGWGRRLKFARKPLCMLDIFVLI

KvLR2

9/42

S4

S5

284

ASMVVLGVGSKGVFATSARGIRFLQILRMLHVDROGGTWRLGSSVVFHHRQELITTLTYIGFLGLIFSSYFVYLAE

KvLQT1

256

ASVPVAVGNQGNVLATSL-RSLRFLQILRMLRMDRRGGTWKLLGSAICAHSKELITAWYIGFLTLLSSFLVYLVE

KvLR2

Pore

S6

356

KD-----AVNESGRVEFGSYADALWGWVTVTTTIGYGDKVPTWVGKTIASCFSVFAISFFALPAGILSGGFALKVQ

KvLQT1

333

KDVPEVDAQGEEMKEEFETYADALWGLITLATIGYGDKTPKTWEGRLIAATFSLIGVSFFALPAGILSGGLALKVQ

KvLR2

392

QKQKQKHFN-RQIPAAASLIQTAWRCYAAENPDSSWT//

KvLQT1

372



EQHRQKHFEKRRKPAAE-LIQAAWRYAT-NPNRIDLVGDM//

KvLR2



FIG. 4

10/42


Putamen
Temporal Lobe
Frontal Lobe
Occipital Lobe
Spinal Cord
Medulla
Cerebral Cortex
Cerebellum



Thalamus
Subthalamic Nucleus
Substantia Nigra
Total Brain
Hippocampus
Corpus Callosum
Caudate Nucleus
Amygdala






Pancreas
Kidney
Skeletal Muscle
Liver
Lung
Placenta
Brain
Heart



Kb
9.5 -
7.5 -
4.4 -
2.4 -
1.3 -
FIG. 5A

Kb
9.5 -
7.5 -
4.4 -
2.4 -
1.3 -
FIG. 5B

SUBSTITUTE SHEET (RULE 26)



12 / 42




FIG. 7




FIG. 8B




FIG. 8A




FIG. 9A




FIG. 9B

SUBSTITUTE SHEET (RULE 26)

15 / 42

<p>30 * GAGCAGCACAGGCAGAAACACTTTGAGAAACGGCGGAACCCCTGCGGACAGTCTGATCCAGTCTGCCCTGGAGATTCTATGCTACTAACCTC CTCGTCGTGTCCTGTTGTGAAACTCTTTGCCCGCCTTGGGACGCCCTCCAGACTAGGTCAGACGGACCTCTAAGATACGATGATTGGAG E Q H R Q K H F E K R R N P A A G L I Q S A W R F Y A T N L></p>	<p>60 * 120 * 180 *</p>	<p>90 * 150 * 210 *</p>
<p>TTACGCCACCGACCTGCACCTCCACGTGGCAGTACTACGAGCGGACAGTCACCTGTCCCATGTACAGCTCACAACCTCAACCTATGGGGCC AATGCGTGGCTGGACGTGAGGTGCACCGTCATGATGCTCGCCTGTCTCAGTGACAGGGGTACATGTCGAGTGTGAGTTGGATACCCCGG L R T D L H S T W Q Y Y E R T V T V P M Y S S Q T Q T Y G A></p>	<p>120 * 150 * 180 *</p>	<p>90 * 150 * 210 *</p>
<p>TCCAGACTCATCCACCTCTGAACCAGCTGGAGCTGCTGAGAAACA AGGTCTGAGTAGGGTGGAGACTTGGTCGACCTCGACGACTCTTTGT S R L I P P L N Q L E L L R N></p>	<p>120 * 150 * 180 *</p>	<p>90 * 150 * 210 *</p>

FIG. 9C

SUBSTITUTE SHEET (RULE 26)

16/42

ATG	GTG	CAG	AAG	TCG	CGC	AAC	GGT	GGC	GTG	TAC	CCC	GGC	ACC	AGC	45
M	V	Q	K	S	R	N	G	G	V	Y	P	G	T	S	15
				5					10						
GGG	GAA	AAG	AAG	CTC	AAG	GTG	GGC	TTC	GTG	GGG	CTG	GAC	CCC	GGC	90
G	E	K	K	L	K	V	G	F	V	G	L	D	P	G	30
				20					25						
GCG	CCC	GAC	TCC	ACA	CGC	GAC	GGC	GCG	CTA	CTC	ATC	GCG	GGC	TCC	135
A	P	D	S	T	R	D	G	A	L	L	I	A	G	S	45
				35					40						
GAG	GCC	CCC	AAG	CGC	GGC	AGC	GTT	TTG	AGC	AAG	CCG	CGG	ACG	GGC	180
E	A	P	K	R	G	S	V	L	S	K	P	R	T	G	60
				50					55						
GGC	GCG	GGA	GCC	GGG	AAG	CCC	CCG	AAG	CGC	AAC	GCC	TTC	TAC	CGC	225
G	A	G	A	G	K	P	P	K	R	N	A	F	Y	R	75
				65					70						
AAG	CTG	CAG	AAT	TTC	CTC	TAC	AAC	GTG	CTA	GAG	CGG	CCC	CGC	GGC	270
K	L	Q	N	F	L	Y	N	V	L	E	R	P	R	G	90
				80					85						
TGG	GCG	TTC	ATC	TAC	CAC	GCC	TAC	GTG	TTC	CTT	TTA	GTC	TTC	TCC	315
W	A	F	I	Y	H	A	Y	V	F	L	L	V	F	S	105
				95					100						
TGC	CTT	GTG	CTT	TCT	GTG	TTT	TCC	ACC	ATC	AAG	GAG	TAC	GAG	AAG	360
C	L	V	L	S	V	F	S	T	I	K	E	Y	E	K	120
				110					115						
AGC	TCT	GAG	GGG	GCC	CTC	TAC	ATC	TTG	GAA	ATC	GTG	ACT	ATC	GTG	405
S	S	E	G	A	L	Y	I	L	E	I	V	T	I	V	135
				125					130						
GTA	TTC	GGT	GTT	GAG	TAC	TTT	GTG	AGG	ATC	TGG	GCT	GCA	GGC	TGC	450
V	F	G	V	E	Y	F	V	R	I	W	A	A	G	C	150
				140					145						
TGT	TGC	CGG	TAT	CGA	GGC	TGG	AGG	GGC	AGG	CTC	AAG	TTT	GCC	AGG	495
C	C	R	Y	R	G	W	R	G	R	L	K	F	A	R	165
				155					160						
AAG	CCG	TTC	TGT	GTG	ATT	GAT	ATC	ATG	GTG	CTG	ATT	GCC	TCC	ATT	540
K	P	F	C	V	I	D	I	M	V	L	I	A	S	I	180
				170					175						
GCT	GTG	CTG	GCT	GCT	GGT	TCC	CAG	GGC	AAT	GTC	TTT	GCC	ACA	TCT	585
A	V	L	A	A	G	S	Q	G	N	V	F	A	T	S	195
				185					190						

FIG. 10A

SUBSTITUTE SHEET (RULE 26)

17/42

GCG	CTT	CGG	AGC	TTG	CGG	TTC	TTG	CAA	ATC	TTG	CGG	ATG	ATC	CGT	630
A	L	R	S	L	R	F	L	Q	I	L	R	M	I	R	
				200					205					210	
ATG	GAC	CGG	AGG	GGT	GGC	ACC	TGG	AAG	CTC	TTG	GGA	TCG	GTA	GTC	675
M	D	R	R	G	G	T	W	K	L	L	G	S	V	V	
				215					220					225	
TAC	GCT	CAC	AGC	AAG	GAG	CTG	GTG	ACT	GCC	TGG	TAC	ATT	GGC	TTC	720
Y	A	H	S	K	E	L	V	T	A	W	Y	I	G	F	
				230					235					240	
CTC	TGC	CTC	ATC	CTG	GCC	TCA	TTT	CTG	GTG	TAC	TTG	GCA	GAA	AAG	765
L	C	L	I	L	A	S	F	L	V	Y	L	A	E	K	
				245					250					255	
GGT	GAG	AAT	GAC	CAC	TTT	GAC	ACC	TAC	GCA	GAT	GCA	CTC	TGG	TGG	810
G	E	N	D	H	F	D	T	Y	A	D	A	L	W	W	
				260					265					270	
GGT	CTG	ATC	ACC	CTG	ACG	ACC	ATT	GGC	TAC	GGG	GAC	AAG	TAC	CCT	855
G	L	I	T	L	T	T	I	G	Y	G	D	K	Y	P	
				275					280					285	
CAG	ACC	TGG	AAC	GGG	AGG	CTG	CTG	GCA	GCG	ACC	TTT	ACC	CTC	ATT	900
Q	T	W	N	G	R	L	L	A	A	T	F	T	L	I	
				290					295					300	
GGT	GTC	TCG	TTC	TTT	GCT	CTT	CCT	GCT	GGC	ATT	TTG	GGA	TCC	GGC	945
G	V	S	F	F	A	L	P	A	G	I	L	G	S	G	
				305					310					315	
TTT	GCC	CTG	AAA	GTC	CAA	GAG	CAG	CAT	CGG	CAA	AAA	CAC	TTT	GAG	990
F	A	L	K	V	Q	E	Q	H	R	Q	K	H	F	E	
				320					325					330	
AAA	CGG	CGG	AAC	CCT	GCG	GCA	GGT	CTG	ATC	CAG	TCT	GCC	TGG	AGA	1035
K	R	R	N	P	A	A	G	L	I	Q	S	A	W	R	
				335					340					345	
TTC	TAT	GCT	ACT	AAC	CTC	TCA	CGC	ACC	GAC	CTG	CAC	TCC	ACG	TGG	1080
F	Y	A	T	N	L	S	R	T	D	L	H	S	T	W	
				350					355					360	
CAG	TAC	TAC	GAG	CGG	ACA	GTC	ACT	GTC	CCC	ATG	TAC	AGA	CTC	ATC	1125
Q	Y	Y	E	R	T	V	T	V	P	M	Y	R	L	I	
				365					370					375	
CCA	CCT	CTG	AAC	CAG	CTG	GAG	CTG	CTG	AGG	AAT	CTC	AAG	AGC	AAA	1170
P	P	L	N	Q	L	E	L	L	R	N	L	K	S	K	
				380					385					390	

FIG. 10B

SUBSTITUTE SHEET (RULE 26)

18 / 42

TCT	GGA	CTC	ACC	TTC	AGG	AAG	GAG	CCA	CAG	CCA	GAG	CCA	TCA	CCA	1215
S	G	L	T	F	R	K	E	P	Q	P	E	P	S	P	
				395					400					405	
AGT	CAG	AAG	GTC	AGT	TTG	AAA	GAT	CGT	GTC	TTC	TCC	AGC	CCC	CGA	1260
S	Q	K	V	S	L	K	D	R	V	F	S	S	P	R	
				410					415					420	
GGC	ATG	GCT	GCC	AAG	GGA	AAG	GGG	TCT	CCC	CAG	GCC	CAG	ACG	GTC	1305
G	M	A	A	K	G	K	G	S	P	Q	A	Q	T	V	
				425					430					435	
CGG	CGG	TCC	CCC	AGT	GCG	GAT	CAG	AGT	CTT	GAT	GAC	AGC	CCG	AGC	1350
R	R	S	P	S	A	D	Q	S	L	D	D	S	P	S	
				440					445					450	
AAG	GTG	CCC	AAG	AGC	TGG	AGC	TTT	GGT	GAC	CGC	AGC	CGC	ACA	CGC	1395
K	V	P	K	S	W	S	F	G	D	R	S	R	T	R	
				455					460					465	
CAG	GCT	TTC	CGC	ATC	AAG	GGT	GCT	GCA	TCC	CGG	CAG	AAT	TCA	GAA	1440
Q	A	F	R	I	K	G	A	A	S	R	Q	N	S	E	
				470					475					480	
GCA	AGC	CTC	CCT	GGG	GAG	GAC	ATC	GTA	GAG	GAC	AAC	AAG	AGC	TGT	1485
A	S	L	P	G	E	D	I	V	E	D	N	K	S	C	
				485					490					495	
AAC	TGC	GAG	TTT	GTG	ACT	GAA	GAT	CTT	ACC	CCT	GGC	CTC	AAA	GTT	1530
N	C	E	F	V	T	E	D	L	T	P	G	L	K	V	
				500					505					510	
AGC	ATC	AGA	GCT	GTG	TGT	GTT	ATG	CGG	TTC	TTG	GTA	TCT	AAG	CGA	1575
S	I	R	A	V	C	V	M	R	F	L	V	S	K	R	
				515					520					525	
AAG	TTC	AAA	GAG	AGT	CTG	CGC	CCA	TAT	GAT	GTG	ATG	GAC	GTC	ATC	1620
K	F	K	E	S	L	R	P	Y	D	V	M	D	V	I	
				530					535					540	
GAA	CAG	TAC	TCG	GCT	GGA	CAC	TTG	GAT	ATG	TTG	TCC	CGC	ATC	AAG	1665
E	Q	Y	S	A	G	H	L	D	M	L	S	R	I	K	
				545					550					555	
AGC	CTG	CAG	TCC	AGA	GTG	GAC	CAG	ATT	GTG	GGG	CGG	GGC	CCA	ACA	1710
S	L	Q	S	R	V	D	Q	I	V	G	R	G	P	T	
				560					565					570	
ATA	ACG	GAT	AAG	GAT	CGC	ACC	AAA	GGC	CCA	GCG	GAA	ACG	GAG	CTG	1755
I	T	D	K	D	R	T	K	G	P	A	E	T	E	L	
				575					580					585	

FIG. 10C

SUBSTITUTE SHEET (RULE 26)

19 / 42

CCC	GAA	GAC	CCC	AGC	ATG	ATG	GGA	CGG	CTT	GGG	AAG	GTG	GAG	AAA	1800
P	E	D	P	S	M	M	G	R	L	G	K	V	E	K	
				590					595					600	
CAG	GTC	TTG	TCC	ATG	GAA	AAG	AAG	CTC	GAC	TTC	TTG	GTG	AGC	ATC	1845
Q	V	L	S	M	E	K	K	L	D	F	L	V	S	I	
				605					610					615	
TAT	ACA	CAG	AGA	ATG	GGC	ATC	CCA	CCA	GCA	GAG	ACA	GAG	GCC	TAT	1890
Y	T	Q	R	M	G	I	P	P	A	E	T	E	A	Y	
				620					625					630	
TTT	GGG	GCC	AAG	GAG	CCT	GAG	CCG	GCA	CCA	CCC	TAC	CAC	AGC	CCA	1935
F	G	A	K	E	P	E	P	A	P	P	Y	H	S	P	
				635					640					645	
GAG	GAC	AGC	CGT	GAC	CAT	GCA	GAC	AAG	CAT	GGC	TGT	ATC	ATT	AAG	1980
E	D	S	R	D	H	A	D	K	H	G	C	I	I	K	
				650					655					660	
ATC	GTC	CGC	TCC	ACC	AGC	TCT	ACG	GGC	CAG	AGG	AAC	TAC	GCA	GCA	2025
I	V	R	S	T	S	S	T	G	Q	R	N	Y	A	A	
				665					670					675	
CCC	CCA	GCC	ATC	CCC	CCT	GCC	CAG	TGT	CCT	CCC	TCC	ACC	TCG	TGG	2070
P	P	A	I	P	P	A	Q	C	P	P	S	T	S	W	
				680					685					690	
CAG	CAG	AGC	CAC	CAG	CGC	CAT	GGC	ACC	TCC	CCT	GTG	GGA	GAC	CAT	2115
Q	Q	S	H	Q	R	H	G	T	S	P	V	G	D	H	
				695					700					705	
GGC	TCA	CTG	GTC	CTG	CGA	CTG	GAG	AGG	AGT	GCT	GGC	ATG	ATG	AGC	2160
G	S	L	V	L	R	L	E	R	S	A	G	M	M	S	
				710					715					720	
TGT	CAC	TAG													2169
C	H	*													

FIG. 10D

20 / 42




FIG. 10E

21 / 42

brainKvLQT-R
heartKvLQT

1 M V Q K S R N G G V Y P G T S G E K K L K V G F V G L D P G A P D S T R D G A L L I A G S E A P K R G S V L S K P R T G
1 M - - - - - S T P V S P A P A P A D L G P R P R V S L D P R V - - - - - S I Y S A R R P L L A R T H I Q

61 G A G A G K P P K R N A F Y R K L Q N E L Y N V L E R P R G W A - E I Y H A Y V F L L V F S C L V L S V F S T I K E Y E
43 G R - - - - - V Y N F L E R P T G W K C E V Y H F T V E L I V L V C L I F S V L S T I E Q Y A

120 K S S E G A L Y I L E I V T I I V V E G V E Y F F V R I W A A G C C C R Y R G M R G R L K F A R K P F C V I D I M V L I A S
85 A L A T G T L F W M E I V L V F F G T E Y V V R L W S A G C C R S K Y V G I W G R L R F A R K P I S I I D L I M V V A S

180 I A V L A A G S Q G N V F A T S A L R S L R F L Q I L R M I R M D R R G G T W K L L G S V V Y A H S K E L V T A W Y I G
145 M V L C V G S K G Q V F A T S A I R G I R F L Q I L R M L H V D R Q G G T W R L L G S V V F I H R Q E L I T T L Y I G

240 F L C L I L A S F L V Y L A E K G E N D H - - - - - E D T Y A D A L W W G L I T L T T I G Y G D K Y P O T W N G R L L A
205 F L G L I F S S Y F V Y L A E K D A V N E S G R I E F G S Y A D A L W W G V V T V T T I G Y G D K V P O T W V G K T I A

295 A T F T L I G V S E F F A L P A G I L G S G F A L K V Q E Q H R Q K H F E K R R N P A A G L I Q S A W R F Y A T N L S R T
265 S C F S V F A I S E F F A L P A G I L G S G F A L K V Q Q K Q R Q K H F N R Q I P A A A S L I Q T A W R C Y A A E N P D S

355 D L H S T W Q Y Y E R T V T V P M Y R L I P P L N Q L E L L R N L K S K S G L T F R K E P Q P E P S P S Q K V S L K D R
325 - - - A T W K I Y V R K P A R S H T L L S P S P K P K S V M V K K K - - - - - E K L D K D N G M S P G E K M - - - - -

415 V E S S P R G M A A K G K G S P Q A Q T V R R S P S A D Q S L D D S K V P F F F G D R S R T R Q A F R I K G A A
373 - E N V P H - - - - - I T Y D P P E D R R P D H F S I D G Y D S S V R K S E T L L E L S - - - - - T P H F L R T N S F A

475 S R Q N S E A S L P G E D I V E D N K S C N C E F V T E D L T P G L K V S I R A V C V M R F L V S K R K F K E S L R P Y
422 - - - - - E D L D L E G E T L L T P I T H - - - - - V S Q L R D H H R A T I K V I R R M Q Y F V A K K E Q Q A R K P Y

535 D V M D V I E Q Y S A G H L D M L S R I K S L Q S R V D Q I V G R G P - - - - - T I T D K D R T K G P A E T E L P E D P S M
472 D V R D V I E Q Y S Q G H L N L M V R I K E L Q R R L D Q S I G K P S L F I P I S E K S K D R G S N T I G - - - - -

592 M G R L G K V E K Q V L S M E K K L D F L V S I Y T Q R M G I P P A E T E A Y F G A K E P E P A P P Y H S P E D S R D H
525 - A R L N R V E D K V T Q L D Q R L V I I T D M L H Q L L S M - Q


652 A D K H G C I I K I V R S T S S T G Q R N Y A A P P A I P P A Q C P P S T S W Q Q S H Q R H G T S P V G D H G S L V L R
556 Q G G P T C N S R S Q V V A S N E G G - - - - - S I N P E L F L P S N S L P T Y E Q L T V P Q T G P D E G S - - - - -

712 L E R S A G M M S C H
605 - - - - - S

FIG. 11

SUBSTITUTE SHEET (RULE 26)

22/42

Splice Variant Analysis

A. S S Q T Q T Y G A S

B. K G S P C R G P L C G C C P G R S S

FIG. 12

23/42




FIG. 13

FIG. 14A




FIG. 14B





FIG. 14C




FIG. 14D




FIG. 15A

Uninjected Control




FIG. 15B

26/ 42

Consensus	-----C-----G-----CC-----AAG-G-AAC***GCC---TACCG-----T-CA-A-TTT--TCTAC-ACG--
hKvLR2	AAGACCCCGCTGAGCGGCCAGTCAAGAGAAACAACGCCAAGTACCGGGCGCATCCAAACTTTGATCTACGACGCC
hKvLR1	GGCGGGGGCGCGGAAGCCCCCAAGCGCAAC***GCCTTCTACCGCAAGCTGCAGAAATTCCTCTACAACGTG
mKvLR1	GGCGGGGGAGCGGGGAAGCCCCCGAAGCGCAAC***GCCTTCTACCGCAAGCTGCAGAAATTCCTCTACAACGTG
Consensus	CT-GAG-G-CC-CG-GGCTGGCG-T--T-TACCACG-T--GTGTTCCCT--T-GT--T-----TGC-T--T-CTG
hKvLR2	CTGGAGAGACCGCGGGGCTGGCGGCTGCTTTACCACGCGTTGGTGTTCTTGATTTGCTTCCCTGGGGTGTGATTCTG
hKvLR1	CTGGAGCGCGCGCGGCTGGCGGTTTCATCTACCACGCTACGTGTTCTCTCCCTGCTGCTGCTGCTGCTGCTG
mKvLR1	CTAGAGCGGCCCCCGCGGCTGGCGGTTTCATCTACCACGCTACGTGTTCTCTCTTTAGTCTTCTCTGCTGCTGCTGCTT
Consensus	-CTGT--T--CCAC--TCAAGGAGTA-GAGA-----TC-G--G-----CT-----T--TGGA-A----T--C-AT-
hKvLR2	GCTGTCTGACCCACATTCAAGGAGTATGAGACTGTCTCGGGAGACTGGCTTCTGTTACTGGAGACATTTGCTATT
hKvLR1	TCTGTGTTTCCACCATCAAGGAGTATGAGAAGAGCTCGGAGGGGGCCCTCTACATCCTGGAAATCGTGACTATC
mKvLR1	TCTGTGTTTCCACCATCAAGGAGTACGAGAAGAGCTCTGAGGGGGCCCTCTACATCTTGGAAATCGTGACTATC
rKvLR1	AAGGAGTATGAGAAGAGTTCGAGGGGGCCCTCTACATCTTGGAAATCGTGACCATC
Consensus	-T--T-TT-GG-G--GAGT-----TG-G-ATCTGGGC-GC-GG-TG-TG-TGCCG-TAC---GGCTGG-6GGG-
hKvLR2	TTTCATCTTTGGAGCCGAGTTTGCTTTGAGGATCTGGGCTGCTGGATGTTGCTGCCGATACAAAGGCTGGCGGGGC
hKvLR1	GTGGTGTGTTGGCGTGGAGTACTTCGTGCGGATCTGGGCGCAGGCTGCTGCTGCCGGTACCGTGGCTGGAGGGG
mKvLR1	GTGGTATTCGGTGTGAGTACTTTGTGAGGATCTGGGCTGCAGGCTGCTGTTGCCGGTATCGAGGCTGGAGGGGC
rKvLR1	GTGGTATTCGGTGTGAGTACTTTGTGAGAAATCTGGGCTGCAGGCTGCTGCTGCCGGTATCGAGGCTGGAGGGGC

FIG. 16A

27/42

-G-CT-AAGTTTGCC-GGAA-CC-CT-TG--TG-T-GA-ATC-T-GTGCT-AT-GCCTC--T--C-GTG-T-GC-
CGACTGAAGTTTGCCAGGAAGCCCTGTGCATGTTGGACATCTTTGTGCTGATTGCCTCTGTGCCAGTGGTTGCT
|||
CGGCTCAAGTTTGCCCGGAACCGCTCTGTGTGATTGACATCATGGTGTCTATCGCCTCCATTGCGGTGCTGGCC
|||
AGGCTCAAGTTTGCCAGGAAGCCGTTCTGTGTGATTGATATCATGGTGTGCTGATTGCCTCCATTGCTGTGCTGGCT
|||
CGGCTCAAGTTTGCCAGGAAGCCATTCTGTGTGATCGACATCATGGTGTGCTGATTGCCTCCATTGCTGTGCTGGCT

Consensus
hKvLR2
hKvLR1
mKvLR1
rKvLR1

G--GG---CCA-GGCAA-GT--T-GC-AC-TC-***CT-CG-AGC-TGGG-TTC-T-CA-AT--T-CG-ATG-T-
GTGGAAACCAAGGCAATGTTCTTGGCCACCTCC***CTGGGAAGCCTGGCTTCTTGCAGATCCTTGGCATGCTG
|||
GCCGGCTCCAGGGCAACGTTCTTGGCACATCTGGCTCCGGAGCCTGGCTTCTTGCAGATTCTTGGGGATGATC
|||
GCTGGTTCCAGGGCAATGTTCTTGGCACATCTGGCTCCGGAGCTTGGGTTCTTGCAAATCTTGGCGGATGATC
|||
GCTGGCTCCAGGGCAATGTTCTTGTACGCTCGACTTGGAGCTTGGGTTCTTACAAATCTTACGGATGATC

Consensus
hKvLR2
hKvLR1
mKvLR1
rKvLR1

CG-ATGGACCGG-G-GG-GGCACCTGGAAGCT--TGGG-TC-G---TCT--GC-CACAGCAA-GA-CT--T-AC-
CGGATGGACCGGAGAGGTGGCACCTGGAAGCTTCTTGGGCTCAGCCATCTGTGCCACAGCAAGAACTCATCAG
|||
CGCATGGACCGGGGGAGGCACCTGGAAGCTGCTGGGCTCTGTGGTCTATGCCACAGCAAGGAGCTGGTCACT
|||
CGTATGGACCGGAGGGGTGGCACCTGGAAGCTCTTGGGATCGGTAGTCTACGCTCACAGCAAGGAGCTGGTGACT
|||
CGTATGGACCGGAGGGGGCGGCACCTGGAAGCTCCTGGGATCGGTGGTCTACGCTCACAGCAAGGAGCTGGTGACT

Consensus
hKvLR2
hKvLR1
mKvLR1
rKvLR1

GC TGGTACAT GG TTCCT CTCATCCT C TC TT CT GT TAC TGG GA AA ***** GAG
GCCTGGTACATCGGTTTCCTGACACTCATCCTTTCTTCATTCTTGCTACCTGGTTGAGAAAGACGTCCCAGAG
|||
GCCTGGTACATCGGCTTCCTTTGTCTCATCCTGGCCCTCGTTCCTGGTGTACTTGGCAGAGAAG*****GGGGAG
|||
GCCTGGTACATCGGCTTCCTTGCCTCATCCTGGCCCATTTCTGGTGTACTTGGCAGAAAAG*****GGTGAG
|||
GCCTGGTACATTTGGCTTCCTTGCCTCATCCTGGCCCTCGTTTCTGGTGTACTTGGCAGAAAAG*****GGTGAG

Consensus
hKvLR2
hKvLR1
mKvLR1
rKvLR1

FIG. 16B

SUBSTITUTE SHEET (RULE 26)

Consensus	Sequence
hKvLR1	-G-CA-AA-CAC TTTGAGAA--GG-GGAA-CC-GC-GC-G--CT-AT-CAG-C-GCCTGGAG-T--TA-GC-AC-
mKvLR1	CGTCAGAAAGCACTTTGAGAAAGGAGGAAGCCAGCTGCTGAGCTCATTACGGCTGCCTGGAGGTATTATGCTACC
hKvLR2	AGGCAGAAAGCACTTTGAGAGAGGGCGGAACCCGGCAGCAGGCCTGATCCAGTCGGCCTGGAGATTTTACGCCACC
rKvLR1	CGGCAAAAACACTTTGAGAAACGGCGGAACCCCTGCGGCAGGCTCTGATCCAGCTCGCTGGAGATTTCTATGCTACT
	CGGCAAAAACACTTTGAGAAACGGCGGAATCTCTGCGGCAGGCTCTATCCAGTCTGCCTGGAGATTTCTATGCTACT

29 / 42

Consensus	AACC-C----G-A--GACCTG-----C-----G
hKvLR2	AACCCCAACAGGATTGACCTGGTTGGCGACATG
hKvLR1	AACCTCTCGCGCACAGACCTGCACTCCACGTGG
mKvLR1	AACCTCTCACGCACCGACCTGCACTCCACGTGG
rKvLR1	AACCTCTCACGCACCGACCTGCACTCCACGTGG

FIG. 16D

S3

	S3	S4
Consensus	E---RIWAAGCCCRY-GWRGRLKFARKP-C--DI-VLIAS--V-A-G-QGNV-ATS*LRSLRFLQILRM-RMDRRGGTWWLL	
hKvLR2	EFALRIWAAGCCCRYKGWRGRLKFARKPLCMLDIFVLIASVPVAVGNQGNVLATS*LRSLRFLQILRMLRMDRRGGTWWLL 	
hKvLR1	EYFVRIWAAGCCCRYRGWRGRLKFARKPFCVIDIMVLIASIVLAAGSQGNVFATSALRSRFLQILRMIRMDRRGGTWWLL 	
mKvLR1	EYFVRIWAAGCCCRYRGWRGRLKFARKPFCVIDIMVLIASIVLAAGSQGNVFATSALRSRFLQILRMIRMDRRGGTWWLL 	
fKvLR1	EYFVRIWAAGCCCRYRGWRGRLKFARKPFCVIDIMVLIASIVLAAGSQGNVFATSALRSRFLQIIRMIIRMDRRGGTWWLL 	

FIG. 17A

P

S5

Consensus GS---AHSKEL-TAWYIGFL-LIL-SFLVYL-EK*-E-D-*****F-TYADALWGLITL-TIGYGDK-P-TW-GRL-

hKvLR2 GSAICAHSKELITAWYIGFLTLILSSFLVYLVEKDVPEVDAQGEEMKEEFETYADALWGLITLATIGYGDKTPKTWEGRLI
 hKvLR1 GSVVYAHSKELVTAWYIGFLCLILASFLVYLAEK**GENDH*****FDTYADALWGLITLTIGYGDKYPQTWNGRLL
 mKvLR1 GSVVYAHSKELVTAWYIGFLCLILASFLVYLAEK**GENDH*****FDTYADALWGLITLTIGYGDKYPQTWNGRLL
 rKvLR1 GSVVYAHSKELVTAWYIGFLCLILASFLVYLAEK**GENDH*****FDTYADALWGLITLTIGYGDKYPQTWNGRLL

S6

Consensus AATF-LIGVSFFALPAGILGSG-ALKVQEQHRQKHFEKRR-PAA-LIQ-AWR-YATN--R-DL----

hKvLR2 AATFSLIGVSFFALPAGILGSGLALKVQEQHRQKHFEKRRKPAELIQAAWRYATNPNRIDLVGDM
 hKvLR1 AATFTLIGVSFFALPAGILGSGFALKVQEQHRQKHFEKRRNPAAGLIQSAWRFYATNLSRTDLHSTW
 mKvLR1 AATFTLIGVSFFALPAGILGSGFALKVQEQHRQKHFEKRRNPAAGLIQSAWRFYATNLSRTDLHSTW
 rKvLR1 AATFTLIGVSFFALPAGILGSGFALKVQEQHRQKHFEKRRNPAAGLIQSAWRFYATNLSRTDLHSTW

FIG. 17B

32 / 42




FIG. 18A




FIG. 18B




FIG. 18C




FIG. 18D

33 / 42

KCNQ2



FIG. 19A

KCNQ3



FIG. 19B




FIG. 19C




FIG. 19D

SUBSTITUTE SHEET (RULE 26)

34 / 42




FIG. 19E




FIG. 19F

SUBSTITUTE SHEET (RULE 26)

KCNQ2+KCNQ3
KCNE1

KCNQ2+KCNQ3

KCNE1






FIG. 20A

FIG. 20B

FIG. 20C

36 / 42



FIG. 21A




FIG. 21B

SUBSTITUTE SHEET (RULE 26)

37 / 42

FIG. 22A





FIG. 22B

SUBSTITUTE SHEET (RULE 26)

38 / 42

ATG	GCA	TTG	GAG	TTC	CCG	GCG	GCT	AAC	CCA	GCC	GGA	GGG	GAC	GCG	45
M	A	L	E	F	P	A	A	N	P	A	G	G	D	A	15
				5					10						
GCG	GCG	GCC	GGC	GAC	GAG	GAG	CGG	AAA	GTG	GGG	CTG	GCG	CCC	GGC	90
A	A	A	G	D	E	E	R	K	V	G	L	A	P	G	30
				20					25						
GAC	GTG	GAG	CAA	GTC	ACC	TTG	GCG	CTC	GGG	GCC	GGA	GCC	GAC	AAA	135
D	V	E	Q	V	T	L	A	L	G	A	G	A	D	K	45
				35					40						
GAC	GGG	ACC	CTG	CTG	CTG	GAG	GGC	GGC	GGC	CGC	GAC	GAG	GGG	CAG	180
D	G	T	L	L	L	E	G	G	G	R	D	E	G	Q	60
				50					55						
CGG	AGG	ACC	CCG	CAG	GGC	ATC	GGG	CTC	CTG	GCC	AAG	ACC	CCG	CTG	225
R	R	T	P	Q	G	I	G	L	L	A	K	T	P	L	75
				65					70						
AGC	CGC	CCA	GTC	AAG	AGA	AAC	AAC	GCC	AAG	TAC	CGG	CGC	ATC	CAA	270
S	R	P	V	K	R	N	N	A	K	Y	R	R	I	Q	90
				80					85						
ACT	TTG	ATC	TAC	GAC	GCC	CTG	GAG	AGA	CCG	CGG	GGC	TGG	GCG	CTG	315
T	L	I	Y	D	A	L	E	R	P	R	G	W	A	L	105
				95					100						
CTT	TAC	CAC	GCG	TTG	GTG	TTC	CTG	ATT	GTC	CTG	GGG	TGC	TTG	ATT	360
L	Y	H	A	L	V	F	L	I	V	L	G	C	L	I	120
				110					115						
CTG	GCT	GTC	CTG	ACC	ACA	TTC	AAG	GAG	TAT	GAG	ACT	GTC	TCG	GGA	405
L	A	V	L	T	T	F	K	E	Y	E	T	V	S	G	135
				125					130						
GAC	TGG	CTT	CTG	TTA	CTG	GAG	ACA	TTT	GCT	ATT	TTC	ATC	TTT	GGA	450
D	W	L	L	L	L	E	T	F	A	I	F	I	F	G	150
				140					145						
GCC	GAG	TTT	GCT	TTG	AGG	ATC	TGG	GCT	GCT	GGA	TGT	TGC	TGC	CGA	495
A	E	F	A	L	R	I	W	A	A	G	C	C	C	R	165
				155					160						
TAC	AAA	GGC	TGG	CGG	GGC	CGA	CTG	AAG	TTT	GCC	AGG	AAG	CCC	CTG	540
Y	K	G	W	R	G	R	L	K	F	A	R	K	P	L	180
				170					175						
TGC	ATG	TTG	GAC	ATC	TTT	GTG	CTG	ATT	GCC	TCT	GTG	CCA	GTG	GTT	585
C	M	L	D	I	F	V	L	I	A	S	V	P	V	V	195
				185					190						

FIG. 23A

SUBSTITUTE SHEET (RULE 26)

39 / 42

GCT	GTG	GGA	AAC	CAA	GGC	AAT	GTT	CTG	GCC	ACC	TCC	CTG	CGA	AGC	630
A	V	G	N	Q	G	N	V	L	A	T	S	L	R	S	
				200					205					210	
CTG	CGC	TTC	CTG	CAG	ATC	CTG	CGC	ATG	CTG	CGG	ATG	GAC	CGG	AGA	675
L	R	F	L	Q	I	L	R	M	L	R	M	D	R	R	
				215					220					225	
GGT	GGC	ACC	TGG	AAG	CTT	CTG	GGC	TCA	GCC	ATC	TGT	GCC	CAC	AGC	720
G	G	T	W	K	L	L	G	S	A	I	C	A	H	S	
				230					235					240	
AAA	GAA	CTC	ATC	ACG	GCC	TGG	TAC	ATC	GGT	TTC	CTG	ACA	CTC	ATC	765
K	E	L	I	T	A	W	Y	I	G	F	L	T	L	I	
				245					250					255	
CTT	TCT	TCA	TTT	CTT	GTC	TAC	CTG	GTT	GAG	AAA	GAC	GTC	CCA	GAG	810
L	S	S	F	L	V	Y	L	V	E	K	D	V	P	E	
				260					265					270	
GTG	GAT	GCA	CAA	GGA	GAG	GAG	ATG	AAA	GAG	GAG	TTT	GAG	ACC	TAT	855
V	D	A	Q	G	E	E	M	K	E	E	F	E	T	Y	
				275					280					285	
GCA	GAT	GCC	CTG	TGG	TGG	GGC	CTG	ATC	ACA	CTG	GCC	ACC	ATT	GGC	900
A	D	A	L	W	W	G	L	I	T	L	A	T	I	G	
				290					295					300	
TAT	GGA	GAC	AAG	ACA	CCC	AAA	ACG	TGG	GAA	GGC	CGT	CTG	ATT	GCC	945
Y	G	D	K	T	P	K	T	W	E	G	R	L	I	A	
				305					310					315	
GCC	ACC	TTT	TCC	TTA	ATT	GGC	GTC	TCC	TTT	TTT	GCC	CTT	CCA	GCG	990
A	T	F	S	L	I	G	V	S	F	F	A	L	P	A	
				320					325					330	
GGC	ATC	CTG	GGG	TCC	GGG	CTG	GCC	CTC	AAG	GTG	CAG	GAG	CAA	CAC	1035
G	I	L	G	S	G	L	A	L	K	V	Q	E	Q	H	
				335					340					345	
CGT	CAG	AAG	CAC	TTT	GAG	AAA	AGG	AGG	AAG	CCA	GCT	GCT	GAG	CTC	1080
R	Q	K	H	F	E	K	R	R	K	P	A	A	E	L	
				350					355					360	
ATT	CAG	GCT	GCC	TGG	AGG	TAT	TAT	GCT	ACC	AAC	CCC	AAC	AGG	ATT	1125
I	Q	A	A	W	R	Y	Y	A	T	N	P	N	R	I	
				365					370					375	
GAC	CTG	GTG	GCG	ACA	TGG	AGA	TTT	TAT	GAA	TCA	GTC	GTC	TCT	TTT	1170
D	L	V	A	T	W	R	F	Y	E	S	V	V	S	F	
				380					385					390	

FIG. 23B

SUBSTITUTE SHEET (RULE 26)

40/42

CCT	TTC	TTC	AGG	AAA	GAA	CAG	CTG	GAG	GCA	GCA	TCC	AGC	CAA	AAG	1215
P	F	F	R	K	E	Q	L	E	A	A	S	S	Q	K	
				395					400					405	
CTG	GGT	CTC	TTG	GAT	CGG	GTT	CGC	CTT	TCT	AAT	CCT	CGT	GGT	AGC	1260
L	G	L	L	D	R	V	R	L	S	N	P	R	G	S	
				410					415					420	
AAT	ACT	AAA	GGA	AAG	CTA	TTT	ACC	CCT	CTG	AAT	GTA	GAT	GCC	ATA	1305
N	T	K	G	K	L	F	T	P	L	N	V	D	A	I	
				425					430					435	
GAA	GAA	AGT	CCT	TCT	AAA	GAA	CCA	AAG	CCT	GTT	GGC	TTA	AAC	AAT	1350
E	E	S	P	S	K	E	P	K	P	V	G	L	N	N	
				440					445					450	
AAA	GAG	CGT	TTC	CGC	ACG	GCC	TTC	CGC	ATG	AAA	GCC	TAC	GCT	TTC	1395
K	E	R	F	R	T	A	F	R	M	K	A	Y	A	F	
				455					460					465	
TGG	CAG	AGT	TCT	GAA	GAT	GCC	GGG	ACA	GGT	GAC	CCC	ATG	GCG	GAA	1440
W	Q	S	S	E	D	A	G	T	G	D	P	M	A	E	
				470					475					480	
GAC	AGG	GGC	TAT	GGG	AAT	GAC	TTC	CCC	ATC	GAA	GAC	ATG	ATC	CCC	1485
D	R	G	Y	G	N	D	F	P	I	E	D	M	I	P	
				485					490					495	
ACC	CTG	AAG	GCC	GCC	ATC	CGA	GCC	GTC	AGA	ATT	CTA	CAA	TTC	CGT	1530
T	L	K	A	A	I	R	A	V	R	I	L	Q	F	R	
				500					505					510	
CTC	TAT	AAA	AAA	AAA	TTC	AAG	GAG	ACT	TTG	AGG	CCT	TAC	GAT	GTG	1575
L	Y	K	K	K	F	K	E	T	L	R	P	Y	D	V	
				515					520					525	
AAG	GAT	GTG	ATT	GAG	CAG	TAT	TCT	GCC	GGG	CAT	CTC	GAC	ATG	CTT	1620
K	D	V	I	E	Q	Y	S	A	G	H	L	D	M	L	
				530					535					540	
TCC	AGG	ATA	AAG	TAC	CTT	CAG	ACG	AGA	ATA	GAT	ATG	ATT	TTC	ACC	1665
S	R	I	K	Y	L	Q	T	R	I	D	M	I	F	T	
				545					550					555	
CCT	GGA	CCT	CCC	TCC	ACG	CCA	AAA	CAC	AAG	AAG	TCT	CAG	AAA	GGG	1710
P	G	P	P	S	T	P	K	H	K	K	S	Q	K	G	
				560					565					570	
TCA	GCA	TTC	ACC	TTC	CCA	TCC	CAG	CAA	TCT	CCC	AGG	AAT	GAA	CCA	1755
S	A	F	T	F	P	S	Q	Q	S	P	R	N	E	P	
				575					580					585	

FIG. 23C

41/42

TAT	GTA	GCC	AGA	CCA	TCC	ACA	TCA	GAA	ATC	GAA	GAC	CAA	AGC	ATG	1800
Y	V	A	R	P	S	T	S	E	I	E	D	Q	S	M	
				590					595					600	
ATG	GGG	AAG	TTT	GTA	AAA	GTT	GAA	AGA	CAG	GTT	CAG	GAC	ATG	GGG	1845
M	G	K	F	V	K	V	E	R	Q	V	Q	D	M	G	
				605					610					615	
AAG	AAG	CTG	GAC	TTC	CTC	GTG	GAT	ATG	CAC	ATG	CAA	CAC	ATG	GAA	1890
K	K	L	D	F	L	V	D	M	H	M	Q	H	M	E	
				620					625					630	
CGG	TTG	CAG	GTG	CAG	GTC	ACG	GAG	TAT	TAC	CCA	ACC	AAG	GGC	ACC	1935
R	L	Q	V	Q	V	T	E	Y	Y	P	T	K	G	T	
				635					640					645	
TCC	TCG	CCA	GCT	GAA	GCA	GAG	AAG	AAG	GAG	GAC	AAC	AGG	TAT	TCC	1980
S	S	P	A	E	A	E	K	K	E	D	N	R	Y	S	
				650					655					660	
GAT	TTG	AAA	ACC	ATC	ATC	TGC	AAC	TAT	TCT	GAG	ACA	GGC	CCC	CCG	2025
D	L	K	T	I	I	C	N	Y	S	E	T	G	P	P	
				665					670					675	
GAA	CCA	CCC	TAC	AGC	TTC	CAC	CAG	GTG	ACC	ATT	GAC	AAA	GTC	AGC	2070
E	P	P	Y	S	F	H	Q	V	T	I	D	K	V	S	
				680					685					690	
CCC	TAT	GGG	TTT	TTT	GCA	CAT	GAC	CCT	GTG	AAC	CTG	CCC	CGA	GGG	2115
P	Y	G	F	F	A	H	D	P	V	N	L	P	R	G	
				695					700					705	
GGA	CCC	AGT	TCT	GGA	AAG	GTT	CAG	GCA	ACT	CCT	CCT	TCC	TCA	GCA	2160
G	P	S	S	G	K	V	Q	A	T	P	P	S	S	A	
				710					715					720	
ACA	ACG	TAT	GTG	GAG	AGG	CCC	ACG	GTC	CTG	CCT	ATC	TTG	ACT	CTT	2205
T	T	Y	V	E	R	P	T	V	L	P	I	L	T	L	
				725					730					735	
CTC	GAC	TCC	CGA	GTG	AGC	TGC	CAC	TCC	CAG	GCT	GAC	CTG	CAG	GGC	2250
L	D	S	R	V	S	C	H	S	Q	A	D	L	Q	G	
				740					745					750	
CCC	TAC	TCG	GAC	CGA	ATC	TCC	CCC	CGG	CAG	AGA	CGT	AGC	ATC	ACG	2295
P	Y	S	D	R	I	S	P	R	Q	R	R	S	I	T	
				755					760					765	
CGA	GAC	AGT	GAC	ACA	CCT	CTG	TCC	CTG	ATG	TCG	GTC	AAC	CAC	GAG	2340
R	D	S	D	T	P	L	S	L	M	S	V	N	H	E	
				770					775					780	

FIG. 23D

SUBSTITUTE SHEET (RULE 26)

42/42

GAG	CTG	GAG	AGG	TCT	CCA	AGT	GGC	TTC	AGC	ATC	TCC	CAG	GAC	AGA	2385
E	L	E	R	S	P	S	G	F	S	I	S	Q	D	R	
				785					790					795	
GAT	GAT	TAT	GTG	TTC	GGC	CCC	AAT	GGG	GGG	TCG	AGC	TGG	ATG	AGG	2430
D	D	Y	V	F	G	P	N	G	G	S	S	W	M	R	
				800					805					810	
GAG	AAG	CGG	TAC	CTC	GCC	GAG	GGT	GAG	ACG	GAC	ACA	GAC	ACG	GAC	2475
E	K	R	Y	L	A	E	G	E	T	D	T	D	T	D	
				815					820					825	
CCC	TTC	ACG	CCC	AGC	GGC	TCC	ATG	CCT	CTG	TCG	TCC	ACA	GGG	GAT	2520
P	F	T	P	S	G	S	M	P	L	S	S	T	G	D	
				830					835					840	
GGG	ATT	TCT	GAT	TCA	GTA	TGG	ACC	CCT	TCC	AAT	AAG	CCC	ATT	TAA	2565
G	I	S	D	S	V	W	T	P	S	N	K	P	I	*	
				845					850				854		

FIG. 23E

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/13276

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12N 5/10, 15/12, 15/63

US CL : 435/320.1, 325; 536/23.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/320.1, 325; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, STN, BIOSCIENCE, CAPLUS, MEDLINE, BIOSIS, WPIDS

search terms: potassium channel, KCNQ, KvLQT

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ----- A	BARHANIN et al. K _v LQT1 and Isk (minK) proteins associate to form the I _K cardiac potassium current. Nature. 07 November 1996, Vol. 384, pages 78-80, especially page 78 and figure 1.	1-17 ----- 19



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

G

document member of the same patent family

Date of the actual completion of the international search

29 JULY 1998

Date of mailing of the international search report

81 AUG 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MICHAEL D. PAK

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/13276

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 1-17, 19
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Claims 1-17 and 19 disclose nucleotide sequences. The search was carried to the extent possible without the nucleotide sequence listing.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-17, 19

Remark on Protest

☐
☐

- The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-17, and 19, drawn to an isolated nucleic acid molecule, a vector, and a host cell.

Group II, claim(s) 18, drawn to an isolated KCNQ protein.

Group III, claim(s) 20, drawn to a method of screening a compound.

Group IV, claim(s) 21-22, drawn to an antibody.

The inventions listed as Groups I-IV do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features because the compound of claim 1 is anticipated by BARHANIN et al. and thus does not share a special technical feature with any other group.

Group I does not share special technical feature with any other group because the claimed compounds are not novel as evidenced by BARHANIN et al. (Nature, 1996, Vol. 384, pages 78-80) which discloses a nucleic acid molecule encoding a KvLQT1 channel which comprises a portion of KCNQ2 protein.

The products of inventions I, II, and IV, do not share special technical feature with any other group, because each defines a separate invention over the art.

The method of invention III does not share special technical feature with any other group, because each defines a separate invention over the art.